Trials (Léon Bérard Center): Difference between revisions

From Beacon
(Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Léon Bérard Center page '''NCTID''': NCT01222767 '''Title''': Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy '''Study Summary''': This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Loc...")
 
No edit summary
 
(8 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{forpatients}}
<span style="display:none">forpatients</span>
{{forproviders}}
<span style="display:none">forproviders</span>
{{forresearchers}}
<span style="display:none">forresearchers</span>
<span style="display:none">francecountry</span>
Go back to [[Léon Bérard Center]] page
Go back to [[Léon Bérard Center]] page
=== Trials: How to participate ===
'''Contact information:''' [https://www.centreleonberard.fr/professionnel-de-sante-chercheur/recherche-contre-le-cancer/la-recherche-clinique-au-centre-leon-berard Click here to access].


'''NCTID''': NCT01222767  
'''NCTID''': NCT01222767  
  '''Title''': Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy  
  '''Title''': [[hasTrialTitle::Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy]]
  '''Study Summary''': This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy to determine the antitumor activity of Zalypsis.  
  '''Study Summary''': This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy to determine the antitumor activity of Zalypsis.  
  '''Sponsor''': PharmaMar  
  '''Sponsor''': PharmaMar  
Line 15: Line 20:
  '''Condition''': Ewing’s Sarcoma  
  '''Condition''': Ewing’s Sarcoma  
'''NCTID''': NCT01798485  
'''NCTID''': NCT01798485  
  '''Title''': A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC  
  '''Title''': [[hasTrialTitle::A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC]]
  '''Study Summary''': The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.  
  '''Study Summary''': The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.  
  '''Sponsor''': Synta Pharmaceuticals Corp.  
  '''Sponsor''': Synta Pharmaceuticals Corp.  
Line 25: Line 30:
  '''Condition''': Non-Small-Cell Lung Adenocarcinoma  
  '''Condition''': Non-Small-Cell Lung Adenocarcinoma  
'''NCTID''': NCT03037385  
'''NCTID''': NCT03037385  
  '''Title''': Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors]]
  '''Study Summary''': This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.  
  '''Study Summary''': This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 35: Line 40:
  '''Condition''': RET-altered Non Small Cell Lung Cancer  
  '''Condition''': RET-altered Non Small Cell Lung Cancer  
'''NCTID''': NCT03336333  
'''NCTID''': NCT03336333  
  '''Title''': A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL  
  '''Title''': [[hasTrialTitle::A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL]]
  '''Study Summary''': To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.  
  '''Study Summary''': To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.  
  '''Sponsor''': BeiGene  
  '''Sponsor''': BeiGene  
Line 45: Line 50:
  '''Condition''': Chronic Lymphocytic Leukemia  
  '''Condition''': Chronic Lymphocytic Leukemia  
'''NCTID''': NCT01882933  
'''NCTID''': NCT01882933  
  '''Title''': D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma  
  '''Title''': [[hasTrialTitle::D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma]]
  '''Study Summary''': A prospective, opened, multicentric, randomised, phase III trial with two arms:  * Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin * Arm B: curative gastrectomy with D1-D2 lymph node dissection  Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology), treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy alone.  
  '''Study Summary''': A prospective, opened, multicentric, randomised, phase III trial with two arms:  * Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin * Arm B: curative gastrectomy with D1-D2 lymph node dissection  Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology), treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy alone.  
  '''Sponsor''': Hospices Civils de Lyon  
  '''Sponsor''': Hospices Civils de Lyon  
Line 55: Line 60:
  '''Condition''': Gastric Adenocarcinoma  
  '''Condition''': Gastric Adenocarcinoma  
'''NCTID''': NCT03038100  
'''NCTID''': NCT03038100  
  '''Title''': A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  
  '''Title''': [[hasTrialTitle::A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer]]
  '''Study Summary''': This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.  
  '''Study Summary''': This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 65: Line 70:
  '''Condition''': Ovarian Cancer  
  '''Condition''': Ovarian Cancer  
'''NCTID''': NCT02500043  
'''NCTID''': NCT02500043  
  '''Title''': Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer  
  '''Title''': [[hasTrialTitle::Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer]]
  '''Study Summary''': The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.  
  '''Study Summary''': The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.  
  '''Sponsor''': Taiho Oncology, Inc.  
  '''Sponsor''': Taiho Oncology, Inc.  
Line 75: Line 80:
  '''Condition''': Refractory Metastatic Gastric Cancer  
  '''Condition''': Refractory Metastatic Gastric Cancer  
'''NCTID''': NCT02947685  
'''NCTID''': NCT02947685  
  '''Title''': Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer  
  '''Title''': [[hasTrialTitle::Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer]]
  '''Study Summary''': The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.  
  '''Study Summary''': The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.  
  '''Sponsor''': Alliance Foundation Trials, LLC.  
  '''Sponsor''': Alliance Foundation Trials, LLC.  
Line 85: Line 90:
  '''Condition''': HER-2 Positive Breast Cancer  
  '''Condition''': HER-2 Positive Breast Cancer  
'''NCTID''': NCT03940703  
'''NCTID''': NCT03940703  
  '''Title''': A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)  
  '''Title''': [[hasTrialTitle::A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)]]
  '''Study Summary''': This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).  
  '''Study Summary''': This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
Line 95: Line 100:
  '''Condition''': Non-small Cell Lung Cancer  
  '''Condition''': Non-small Cell Lung Cancer  
'''NCTID''': NCT01322490  
'''NCTID''': NCT01322490  
  '''Title''': A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer  
  '''Title''': [[hasTrialTitle::A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer]]
  '''Study Summary''': The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.  
  '''Study Summary''': The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.  
  '''Sponsor''': Bavarian Nordic  
  '''Sponsor''': Bavarian Nordic  
Line 105: Line 110:
  '''Condition''': Prostate Cancer Metastatic  
  '''Condition''': Prostate Cancer Metastatic  
'''NCTID''': NCT03493854  
'''NCTID''': NCT03493854  
  '''Title''': A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer  
  '''Title''': [[hasTrialTitle::A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer]]
  '''Study Summary''': This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.  
  '''Study Summary''': This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 115: Line 120:
  '''Condition''': Early Breast Cancer  
  '''Condition''': Early Breast Cancer  
'''NCTID''': NCT04704154  
'''NCTID''': NCT04704154  
  '''Title''': A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors  
  '''Title''': [[hasTrialTitle::A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors]]
  '''Study Summary''': Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.  In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts.  The trial will include about 200 participants who are at least 18 years old. All of the participants will take 90 mg of regorafenib as a tablet by mouth. The dose of regorafenib can be adjusted up to 120 mg or down to 60 mg by the doctor based on how well a participant tolerates treatment. All of the participants will receive 480 milligrams (mg) of nivolumab through a needle put into a vein (IV infusion).  The participants will take treatments in 4-week periods called cycles. They will take regorafenib once a day for 3 weeks, then stop for 1 week. In each cycle, the participants will receive nivolumab one time. These 4-week cycles will be repeated throughout the trial. The participants can take nivolumab and regorafenib until their cancer gets worse, until they have medical problems, or until they leave the trial. The longest nivolumab can be given is up to 2 years.  During the trial, the doctors will take pictures of the participants’ tumors using CT or MRI and will take blood and urine samples. The doctors will also do physical examinations and check the participants’ heart health using an electrocardiogram (ECG). They will ask questions about how the participants are feeling and if they have any medical problems.  
  '''Study Summary''': Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.  In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts.  The trial will include about 200 participants who are at least 18 years old. All of the participants will take 90 mg of regorafenib as a tablet by mouth. The dose of regorafenib can be adjusted up to 120 mg or down to 60 mg by the doctor based on how well a participant tolerates treatment. All of the participants will receive 480 milligrams (mg) of nivolumab through a needle put into a vein (IV infusion).  The participants will take treatments in 4-week periods called cycles. They will take regorafenib once a day for 3 weeks, then stop for 1 week. In each cycle, the participants will receive nivolumab one time. These 4-week cycles will be repeated throughout the trial. The participants can take nivolumab and regorafenib until their cancer gets worse, until they have medical problems, or until they leave the trial. The longest nivolumab can be given is up to 2 years.  During the trial, the doctors will take pictures of the participants’ tumors using CT or MRI and will take blood and urine samples. The doctors will also do physical examinations and check the participants’ heart health using an electrocardiogram (ECG). They will ask questions about how the participants are feeling and if they have any medical problems.  
  '''Sponsor''': Bayer  
  '''Sponsor''': Bayer  
Line 125: Line 130:
  '''Condition''': Solid Tumors  
  '''Condition''': Solid Tumors  
'''NCTID''': NCT03520075  
'''NCTID''': NCT03520075  
  '''Title''': Study of ASTX029 in Subjects With Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::Study of ASTX029 in Subjects With Advanced Solid Tumors]]
  '''Study Summary''': This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.  
  '''Study Summary''': This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.  
  '''Sponsor''': Astex Pharmaceuticals, Inc.  
  '''Sponsor''': Astex Pharmaceuticals, Inc.  
Line 135: Line 140:
  '''Condition''': Solid Tumor, Adult  
  '''Condition''': Solid Tumor, Adult  
'''NCTID''': NCT02098343  
'''NCTID''': NCT02098343  
  '''Title''': p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246  
  '''Title''': [[hasTrialTitle::p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246]]
  '''Study Summary''': The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll up to a maximum of 400 patients.  
  '''Study Summary''': The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll up to a maximum of 400 patients.  
  '''Sponsor''': Aprea Therapeutics  
  '''Sponsor''': Aprea Therapeutics  
Line 145: Line 150:
  '''Condition''': Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53  
  '''Condition''': Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53  
'''NCTID''': NCT04197986  
'''NCTID''': NCT04197986  
  '''Title''': Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations  
  '''Title''': [[hasTrialTitle::Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations]]
  '''Study Summary''': This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or rearrangements) who have disease that is considered at high risk for recurrence with surgery alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and/or nephrectomy. Study treatment is randomized 1:1 between infigratinib or placebo with treatment up to 1 year or until invasive local, distal, or metastatic disease recurrence confirmed by independent imaging reviewer.  
  '''Study Summary''': This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or rearrangements) who have disease that is considered at high risk for recurrence with surgery alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and/or nephrectomy. Study treatment is randomized 1:1 between infigratinib or placebo with treatment up to 1 year or until invasive local, distal, or metastatic disease recurrence confirmed by independent imaging reviewer.  
  '''Sponsor''': QED Therapeutics, Inc.  
  '''Sponsor''': QED Therapeutics, Inc.  
Line 155: Line 160:
  '''Condition''': Upper Tract Urothelial Carcinomas  
  '''Condition''': Upper Tract Urothelial Carcinomas  
'''NCTID''': NCT04300556  
'''NCTID''': NCT04300556  
  '''Title''': A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types  
  '''Title''': [[hasTrialTitle::A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types]]
  '''Study Summary''': The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer <math display="block">OC</math>, endometrial cancer <math display="block">EC</math>, non-small cell lung carcinoma <math display="block">NSCLC</math>, triple-negative breast cancer <math display="block">TNBC</math>), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A <math display="block">OC and EC participants</math> and Part B <math display="block">EC only</math>): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the use of the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days, as mitigation strategy for interstitial lung disease (ILD); and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to further evaluate the safety, tolerability and preliminary efficacy of 2 treatment regimens with farletuzumab ecteribulin (MORAb-202) in participants with advanced EC and to determine the recommended treatment regimen for further development of farletuzumab ecteribulin (MORAb-202).  
  '''Study Summary''': The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer <math display="block">OC</math>, endometrial cancer <math display="block">EC</math>, non-small cell lung carcinoma <math display="block">NSCLC</math>, triple-negative breast cancer <math display="block">TNBC</math>), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A <math display="block">OC and EC participants</math> and Part B <math display="block">EC only</math>): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the use of the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days, as mitigation strategy for interstitial lung disease (ILD); and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to further evaluate the safety, tolerability and preliminary efficacy of 2 treatment regimens with farletuzumab ecteribulin (MORAb-202) in participants with advanced EC and to determine the recommended treatment regimen for further development of farletuzumab ecteribulin (MORAb-202).  
  '''Sponsor''': Eisai Inc.  
  '''Sponsor''': Eisai Inc.  
Line 165: Line 170:
  '''Condition''': Solid Tumor  
  '''Condition''': Solid Tumor  
'''NCTID''': NCT01956812  
'''NCTID''': NCT01956812  
  '''Title''': Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan &amp; Gemcitabine vs Placebo &amp; Gemcitabine in Metastatic Pancreatic Cancer  
  '''Title''': [[hasTrialTitle::Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan &amp; Gemcitabine vs Placebo &amp; Gemcitabine in Metastatic Pancreatic Cancer]]
  '''Study Summary''': The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).  
  '''Study Summary''': The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).  
  '''Sponsor''': Gilead Sciences  
  '''Sponsor''': Gilead Sciences  
Line 175: Line 180:
  '''Condition''': Metastatic Pancreatic Cancer  
  '''Condition''': Metastatic Pancreatic Cancer  
'''NCTID''': NCT04597125  
'''NCTID''': NCT04597125  
  '''Title''': Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH  
  '''Title''': [[hasTrialTitle::Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH]]
  '''Study Summary''': Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The NAH drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer.  Participants in this study will receive either Radium-223 dichloride or a NAH therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral NAH therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain.  
  '''Study Summary''': Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The NAH drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer.  Participants in this study will receive either Radium-223 dichloride or a NAH therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral NAH therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain.  
  '''Sponsor''': Bayer  
  '''Sponsor''': Bayer  
Line 185: Line 190:
  '''Condition''': Metastatic Castrate Resistant Prostate Cancer (mCRPC)  
  '''Condition''': Metastatic Castrate Resistant Prostate Cancer (mCRPC)  
'''NCTID''': NCT01578655  
'''NCTID''': NCT01578655  
  '''Title''': Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer  
  '''Title''': [[hasTrialTitle::Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer]]
  '''Study Summary''': This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter, international trial. Treatment will consist of cabazitaxel/prednisone/custirsen vs. cabazitaxel/prednisone. A total of approximately 630 patients will be randomized with equal probability to the two arms.  
  '''Study Summary''': This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter, international trial. Treatment will consist of cabazitaxel/prednisone/custirsen vs. cabazitaxel/prednisone. A total of approximately 630 patients will be randomized with equal probability to the two arms.  
  '''Sponsor''': Achieve Life Sciences  
  '''Sponsor''': Achieve Life Sciences  
Line 195: Line 200:
  '''Condition''': Prostate Cancer  
  '''Condition''': Prostate Cancer  
'''NCTID''': NCT00789633  
'''NCTID''': NCT00789633  
  '''Title''': Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer  
  '''Title''': [[hasTrialTitle::Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer]]
  '''Study Summary''': The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.  
  '''Study Summary''': The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.  
  '''Sponsor''': AB Science  
  '''Sponsor''': AB Science  
Line 205: Line 210:
  '''Condition''': Pancreatic Cancer  
  '''Condition''': Pancreatic Cancer  
'''NCTID''': NCT02438007  
'''NCTID''': NCT02438007  
  '''Title''': A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC  
  '''Title''': [[hasTrialTitle::A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC]]
  '''Study Summary''': The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).  
  '''Study Summary''': The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).  
  '''Sponsor''': LTN PHARMACEUTICALS, INC.  
  '''Sponsor''': LTN PHARMACEUTICALS, INC.  
Line 215: Line 220:
  '''Condition''': Prostate Cancer  
  '''Condition''': Prostate Cancer  
'''NCTID''': NCT04189445  
'''NCTID''': NCT04189445  
  '''Title''': Futibatinib in Patients With Specific FGFR Aberrations  
  '''Title''': [[hasTrialTitle::Futibatinib in Patients With Specific FGFR Aberrations]]
  '''Study Summary''': The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma <math display="block">iCCA</math>); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.  
  '''Study Summary''': The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma <math display="block">iCCA</math>); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.  
  '''Sponsor''': Taiho Oncology, Inc.  
  '''Sponsor''': Taiho Oncology, Inc.  
Line 225: Line 230:
  '''Condition''': Advanced or Metastatic Solid Tumor  
  '''Condition''': Advanced or Metastatic Solid Tumor  
'''NCTID''': NCT02471716  
'''NCTID''': NCT02471716  
  '''Title''': Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor  
  '''Title''': [[hasTrialTitle::Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor]]
  '''Study Summary''': This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.  
  '''Study Summary''': This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.  
  '''Sponsor''': Five Prime Therapeutics, Inc.  
  '''Sponsor''': Five Prime Therapeutics, Inc.  
Line 235: Line 240:
  '''Condition''': Pigmented Villonodular Synovitis  
  '''Condition''': Pigmented Villonodular Synovitis  
'''NCTID''': NCT02983045  
'''NCTID''': NCT02983045  
  '''Title''': A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors]]
  '''Study Summary''': In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3.  
  '''Study Summary''': In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3.  
  '''Sponsor''': Nektar Therapeutics  
  '''Sponsor''': Nektar Therapeutics  
Line 245: Line 250:
  '''Condition''': Melanoma  
  '''Condition''': Melanoma  
'''NCTID''': NCT03485209  
'''NCTID''': NCT03485209  
  '''Title''': Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors  
  '''Title''': [[hasTrialTitle::Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors]]
  '''Study Summary''': This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study.  * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: ** Pembrolizumab or, ** Pembrolizumab and carboplatin, or ** Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.  
  '''Study Summary''': This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study.  * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: ** Pembrolizumab or, ** Pembrolizumab and carboplatin, or ** Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.  
  '''Sponsor''': Seagen Inc.  
  '''Sponsor''': Seagen Inc.  
Line 255: Line 260:
  '''Condition''': Colorectal Neoplasms  
  '''Condition''': Colorectal Neoplasms  
'''NCTID''': NCT04901806  
'''NCTID''': NCT04901806  
  '''Title''': Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors  
  '''Title''': [[hasTrialTitle::Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors]]
  '''Study Summary''': This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.  
  '''Study Summary''': This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.  
  '''Sponsor''': Pyramid Biosciences  
  '''Sponsor''': Pyramid Biosciences  
Line 265: Line 270:
  '''Condition''': Solid Tumor, Adult  
  '''Condition''': Solid Tumor, Adult  
'''NCTID''': NCT00312845  
'''NCTID''': NCT00312845  
  '''Title''': Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma  
  '''Title''': [[hasTrialTitle::Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma]]
  '''Study Summary''': The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.  
  '''Study Summary''': The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.  
  '''Sponsor''': Millennium Pharmaceuticals, Inc.  
  '''Sponsor''': Millennium Pharmaceuticals, Inc.  
Line 275: Line 280:
  '''Condition''': Non-Hodgkin’s Lymphoma  
  '''Condition''': Non-Hodgkin’s Lymphoma  
'''NCTID''': NCT01310816  
'''NCTID''': NCT01310816  
  '''Title''': A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma  
  '''Title''': [[hasTrialTitle::A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma]]
  '''Study Summary''': IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.  
  '''Study Summary''': IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.  
  '''Sponsor''': Infinity Pharmaceuticals, Inc.  
  '''Sponsor''': Infinity Pharmaceuticals, Inc.  
Line 285: Line 290:
  '''Condition''': Conventional Chondrosarcoma  
  '''Condition''': Conventional Chondrosarcoma  
'''NCTID''': NCT00069745  
'''NCTID''': NCT00069745  
  '''Title''': Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen  
  '''Title''': [[hasTrialTitle::Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen]]
  '''Study Summary''': PURPOSE:  The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).  TARGET PATIENT POPULATION:  The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria.  WHAT IS SATRAPLATIN:  Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial.  RATIONALE:  There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy  
  '''Study Summary''': PURPOSE:  The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).  TARGET PATIENT POPULATION:  The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria.  WHAT IS SATRAPLATIN:  Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial.  RATIONALE:  There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy  
  '''Sponsor''': Agennix  
  '''Sponsor''': Agennix  
Line 295: Line 300:
  '''Condition''': Prostate Cancer  
  '''Condition''': Prostate Cancer  
'''NCTID''': NCT02730416  
'''NCTID''': NCT02730416  
  '''Title''': Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer  
  '''Title''': [[hasTrialTitle::Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer]]
  '''Study Summary''': This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer.  
  '''Study Summary''': This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer.  
  '''Sponsor''': Nordic Society of Gynaecological Oncology - Clinical Trials Unit  
  '''Sponsor''': Nordic Society of Gynaecological Oncology - Clinical Trials Unit  
Line 305: Line 310:
  '''Condition''': Endometrial Cancer  
  '''Condition''': Endometrial Cancer  
'''NCTID''': NCT02684006  
'''NCTID''': NCT02684006  
  '''Title''': A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)  
  '''Title''': [[hasTrialTitle::A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)]]
  '''Study Summary''': This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma  
  '''Study Summary''': This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma  
  '''Sponsor''': Pfizer  
  '''Sponsor''': Pfizer  
Line 315: Line 320:
  '''Condition''': Renal Cell Cancer  
  '''Condition''': Renal Cell Cancer  
'''NCTID''': NCT02383927  
'''NCTID''': NCT02383927  
  '''Title''': Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations  
  '''Title''': [[hasTrialTitle::Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations]]
  '''Study Summary''': Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head &amp; Neck SCC) and cohort 3 (Other SCC) are currently open  
  '''Study Summary''': Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head &amp; Neck SCC) and cohort 3 (Other SCC) are currently open  
  '''Sponsor''': Kura Oncology, Inc.  
  '''Sponsor''': Kura Oncology, Inc.  
Line 325: Line 330:
  '''Condition''': Thyroid Cancer  
  '''Condition''': Thyroid Cancer  
'''NCTID''': NCT03424005  
'''NCTID''': NCT03424005  
  '''Title''': A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer  
  '''Title''': [[hasTrialTitle::A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer]]
  '''Study Summary''': This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer.  The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study:  Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line <math display="block">1L</math> PD-L1+ cohort).  Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line <math display="block">2L</math> CIT-naive cohort).  Cohort 3 will consist of participants with locally-advanced or metastatic HR+, HER2-negative disease with PIK3CA mutation who may or may not have had disease progression during or following previous lines of treatment for metastatic disease (HR+cohort).  Cohort 4 will consist of participants with locally-advanced or metastatic HER2+ /HER2-low disease with PIK3CA mutation who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort).  In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). In addition, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.  
  '''Study Summary''': This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer.  The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study:  Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line <math display="block">1L</math> PD-L1+ cohort).  Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line <math display="block">2L</math> CIT-naive cohort).  Cohort 3 will consist of participants with locally-advanced or metastatic HR+, HER2-negative disease with PIK3CA mutation who may or may not have had disease progression during or following previous lines of treatment for metastatic disease (HR+cohort).  Cohort 4 will consist of participants with locally-advanced or metastatic HER2+ /HER2-low disease with PIK3CA mutation who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort).  In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). In addition, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 335: Line 340:
  '''Condition''': Breast Cancer  
  '''Condition''': Breast Cancer  
'''NCTID''': NCT01732926  
'''NCTID''': NCT01732926  
  '''Title''': Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas  
  '''Title''': [[hasTrialTitle::Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas]]
  '''Study Summary''': The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).  An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).  
  '''Study Summary''': The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).  An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).  
  '''Sponsor''': Gilead Sciences  
  '''Sponsor''': Gilead Sciences  
Line 345: Line 350:
  '''Condition''': Indolent Non-Hodgkin’s Lymphomas  
  '''Condition''': Indolent Non-Hodgkin’s Lymphomas  
'''NCTID''': NCT03456063  
'''NCTID''': NCT03456063  
  '''Title''': A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)  
  '''Title''': [[hasTrialTitle::A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) ]]
  '''Study Summary''': This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.  
  '''Study Summary''': This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 355: Line 360:
  '''Condition''': Non-Small-Cell Lung  
  '''Condition''': Non-Small-Cell Lung  
'''NCTID''': NCT03410693  
'''NCTID''': NCT03410693  
  '''Title''': Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma  
  '''Title''': [[hasTrialTitle::Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma]]
  '''Study Summary''': This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.  The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in terms of objective response rate (before: overall survivial) of urothelial carcinoma patients with FGFR positive tumors.  At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied.  
  '''Study Summary''': This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.  The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in terms of objective response rate (before: overall survivial) of urothelial carcinoma patients with FGFR positive tumors.  At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied.  
  '''Sponsor''': Bayer  
  '''Sponsor''': Bayer  
Line 365: Line 370:
  '''Condition''': Carcinoma, Transitional Cell  
  '''Condition''': Carcinoma, Transitional Cell  
'''NCTID''': NCT01846416  
'''NCTID''': NCT01846416  
  '''Title''': A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]  
  '''Title''': [[hasTrialTitle::A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] ]]  
  '''Study Summary''': This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression.  Eligible participants will be categorized in to three groups as follows:  # Participants with no prior chemotherapy for advanced disease; # Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); # Participants who are 2L+ and previously treated for brain metastases.  
  '''Study Summary''': This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression.  Eligible participants will be categorized in to three groups as follows:  # Participants with no prior chemotherapy for advanced disease; # Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); # Participants who are 2L+ and previously treated for brain metastases.  
  '''Sponsor''': Genentech, Inc.  
  '''Sponsor''': Genentech, Inc.  
Line 375: Line 380:
  '''Condition''': Non-Small Cell Lung Cancer  
  '''Condition''': Non-Small Cell Lung Cancer  
'''NCTID''': NCT03136627  
'''NCTID''': NCT03136627  
  '''Title''': Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC  
  '''Title''': [[hasTrialTitle::Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC]]
  '''Study Summary''': This study will evaluate the safety, tolerability, dose-limiting toxicities, MTD, and preliminary anti-tumor activity of tivozanib in combination with nivolumab in subjects with metastatic renal cell cancer. This will use a standard ‘3+3’ dose-escalation trial design. A cohort of 3 subjects will be enrolled at each dose level. If 1 of 3 subjects experiences a DLT during Cycle 1, that dose level will be expanded to 6 subjects. If 0 of 3 or ≤ 1 of 6 subjects experience a DLT during Cycle 1, escalation to the next dose will occur. If ≥ 2 of 6 subjects experience a DLT during Cycle 1, dose escalation will stop and the prior dose will be considered the MTD. This is a validated trial design for Phase 1 trials.  Following completion of the dose-escalation cohorts and determination of MTD, an expansion cohort of up to 20 subjects may be enrolled at MTD to further evaluate safety, tolerability, and preliminary anti-tumor activity of tivozanib in combination with nivolumab in the same target population.  
  '''Study Summary''': This study will evaluate the safety, tolerability, dose-limiting toxicities, MTD, and preliminary anti-tumor activity of tivozanib in combination with nivolumab in subjects with metastatic renal cell cancer. This will use a standard ‘3+3’ dose-escalation trial design. A cohort of 3 subjects will be enrolled at each dose level. If 1 of 3 subjects experiences a DLT during Cycle 1, that dose level will be expanded to 6 subjects. If 0 of 3 or ≤ 1 of 6 subjects experience a DLT during Cycle 1, escalation to the next dose will occur. If ≥ 2 of 6 subjects experience a DLT during Cycle 1, dose escalation will stop and the prior dose will be considered the MTD. This is a validated trial design for Phase 1 trials.  Following completion of the dose-escalation cohorts and determination of MTD, an expansion cohort of up to 20 subjects may be enrolled at MTD to further evaluate safety, tolerability, and preliminary anti-tumor activity of tivozanib in combination with nivolumab in the same target population.  
  '''Sponsor''': AVEO Pharmaceuticals, Inc.  
  '''Sponsor''': AVEO Pharmaceuticals, Inc.  
Line 385: Line 390:
  '''Condition''': Carcinoma, Renal Cell  
  '''Condition''': Carcinoma, Renal Cell  
'''NCTID''': NCT05002127  
'''NCTID''': NCT05002127  
  '''Title''': A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)  
  '''Title''': [[hasTrialTitle::A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)]]
  '''Study Summary''': A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.  
  '''Study Summary''': A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.  
  '''Sponsor''': ALX Oncology Inc.  
  '''Sponsor''': ALX Oncology Inc.  
Line 395: Line 400:
  '''Condition''': Gastric Cancer  
  '''Condition''': Gastric Cancer  
'''NCTID''': NCT03178552  
'''NCTID''': NCT03178552  
  '''Title''': A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)  
  '''Title''': [[hasTrialTitle::A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)]]
  '''Study Summary''': This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.  
  '''Study Summary''': This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 405: Line 410:
  '''Condition''': Non-Small Cell Lung Cancer  
  '''Condition''': Non-Small Cell Lung Cancer  
'''NCTID''': NCT01792726  
'''NCTID''': NCT01792726  
  '''Title''': A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.  
  '''Title''': [[hasTrialTitle::A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer]].  
  '''Study Summary''': TARGIT-Boost is an international randomised clinical trial designed to test the hypothesis that the tumour bed boost delivered as a single dose of targeted intraoperative radiotherapy (TARGIT-B) is superior to the conventional course of external beam radiotherapy boost (EBRT-Boost), especially in women with high risk of local recurrence. It is a pragmatic trial in which each participating centre can use the local predefined inclusion/exclusion criteria for entry into the trial. Only centres with access to the Intrabeam® (Carl Zeiss) are eligible to enter patients into the trial.  Eligible patients are those with a higher risk of local recurrence after breast conserving surgery.  After giving consent patients are randomised to either TARGIT Boost or EBRT Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at six monthly intervals for three years and then annually.  The primary endpoint is ipsilateral breast recurrence rate. Secondary endpoints are relapse-free survival, site of recurrence, overall survival (breast-cancer specific and non-breast cancer deaths) patient satisfaction and quality of life.  
  '''Study Summary''': TARGIT-Boost is an international randomised clinical trial designed to test the hypothesis that the tumour bed boost delivered as a single dose of targeted intraoperative radiotherapy (TARGIT-B) is superior to the conventional course of external beam radiotherapy boost (EBRT-Boost), especially in women with high risk of local recurrence. It is a pragmatic trial in which each participating centre can use the local predefined inclusion/exclusion criteria for entry into the trial. Only centres with access to the Intrabeam® (Carl Zeiss) are eligible to enter patients into the trial.  Eligible patients are those with a higher risk of local recurrence after breast conserving surgery.  After giving consent patients are randomised to either TARGIT Boost or EBRT Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at six monthly intervals for three years and then annually.  The primary endpoint is ipsilateral breast recurrence rate. Secondary endpoints are relapse-free survival, site of recurrence, overall survival (breast-cancer specific and non-breast cancer deaths) patient satisfaction and quality of life.  
  '''Sponsor''': University College, London  
  '''Sponsor''': University College, London  
Line 415: Line 420:
  '''Condition''': Early Breast Cancer  
  '''Condition''': Early Breast Cancer  
'''NCTID''': NCT00083304  
'''NCTID''': NCT00083304  
  '''Title''': Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer  
  '''Title''': [[hasTrialTitle::Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer]]
  '''Study Summary''': RSR13 (efaproxiral) is a radiation sensitizer that has shown positive results in a Phase 3, randomized clinical trial of patients with brain metastases. Of 111 eligible breast cancer patients with brain metastases in that trial, 59 patients who received RSR13 prior to radiation therapy had a median survival time that was twice as long as the 52 patients who did not receive RSR13 prior to radiation therapy.  RSR13 (efaproxiral) is an experimental drug that increases the amount of oxygen released from blood into the tissues. It is well known that certain types of cancer tumors, including those in brain metastases, lack oxygen. Lack of oxygen in a tumor can reduce the effect of radiation therapy (RT). RSR13 may increase the oxygen level in brain tumors so that radiation therapy works better.  This study will enroll up to 360 women with brain metastases from breast cancer, and will evaluate if whole brain radiation therapy given with RSR13 will have a better treatment effect than whole brain radiation therapy alone. RSR13 will be infused intravenously (IV) through a central catheter placed in a central vein. Women randomized (assigned) to receive RSR13, therefore, will need to have a central catheter placed for treatment unless one is already in place.  
  '''Study Summary''': RSR13 (efaproxiral) is a radiation sensitizer that has shown positive results in a Phase 3, randomized clinical trial of patients with brain metastases. Of 111 eligible breast cancer patients with brain metastases in that trial, 59 patients who received RSR13 prior to radiation therapy had a median survival time that was twice as long as the 52 patients who did not receive RSR13 prior to radiation therapy.  RSR13 (efaproxiral) is an experimental drug that increases the amount of oxygen released from blood into the tissues. It is well known that certain types of cancer tumors, including those in brain metastases, lack oxygen. Lack of oxygen in a tumor can reduce the effect of radiation therapy (RT). RSR13 may increase the oxygen level in brain tumors so that radiation therapy works better.  This study will enroll up to 360 women with brain metastases from breast cancer, and will evaluate if whole brain radiation therapy given with RSR13 will have a better treatment effect than whole brain radiation therapy alone. RSR13 will be infused intravenously (IV) through a central catheter placed in a central vein. Women randomized (assigned) to receive RSR13, therefore, will need to have a central catheter placed for treatment unless one is already in place.  
  '''Sponsor''': Spectrum Pharmaceuticals, Inc  
  '''Sponsor''': Spectrum Pharmaceuticals, Inc  
Line 425: Line 430:
  '''Condition''': Breast Cancer  
  '''Condition''': Breast Cancer  
'''NCTID''': NCT04675827  
'''NCTID''': NCT04675827  
  '''Title''': De-escalation Adjuvant Chemo in HER2+/ER-  
  '''Title''': [[hasTrialTitle::De-escalation Adjuvant Chemo in HER2+/ER-ode-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo &amp; Dual HER2 Blockade]]
ode-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo &amp; Dual HER2 Blockade  
  '''Study Summary''': DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II de-escalation study evaluating neoadjuvant treatment with 12 administrations of weekly IV paclitaxel 80 mg/m2 (or IV docetaxel 75 mg/m2 every 3 weeks for 4 cycles) combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab (loading dose of 1200 mg pertuzumab and 600 mg trastuzumab, followed by 600 mg pertuzumab and 600 mg trastuzumab) every 3 weeks for 4 cycles.  Surgery will be performed according to local guidelines in all subjects after neoadjuvant treatment.  After surgery, subjects who achieve a pCR (defined as pT0/Tis pN0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Subjects with residual invasive disease will receive salvage adjuvant trastuzumab emtansine (T-DM1, 3.6 mg/kg, IV every 3 weeks) for 14 cycles. In subjects whose residual invasive disease is classified per RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator’s discretion, before the 14 cycles of T-DM1.  If histopathological analysis finds that the surgical specimen from a subject with residual disease is ER-positive and/or PR-positive, adjuvant endocrine therapy may be administered concomitantly with study treatment, at the investigator’s discretion and according to local guidelines.  Adjuvant radiotherapy will be mandatory after breast-conserving surgery, whereas it will be performed according to local guidelines after mastectomy, and it will be administered concomitantly with pertuzumab and trastuzumab FDC SC in subjects who achieve a pCR, and concomitantly with T-DM1 in subjects with residual invasive disease (after anthracycline-based chemotherapy in subjects assigned to receive this treatment).  
  '''Study Summary''': DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II de-escalation study evaluating neoadjuvant treatment with 12 administrations of weekly IV paclitaxel 80 mg/m2 (or IV docetaxel 75 mg/m2 every 3 weeks for 4 cycles) combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab (loading dose of 1200 mg pertuzumab and 600 mg trastuzumab, followed by 600 mg pertuzumab and 600 mg trastuzumab) every 3 weeks for 4 cycles.  Surgery will be performed according to local guidelines in all subjects after neoadjuvant treatment.  After surgery, subjects who achieve a pCR (defined as pT0/Tis pN0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Subjects with residual invasive disease will receive salvage adjuvant trastuzumab emtansine (T-DM1, 3.6 mg/kg, IV every 3 weeks) for 14 cycles. In subjects whose residual invasive disease is classified per RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator’s discretion, before the 14 cycles of T-DM1.  If histopathological analysis finds that the surgical specimen from a subject with residual disease is ER-positive and/or PR-positive, adjuvant endocrine therapy may be administered concomitantly with study treatment, at the investigator’s discretion and according to local guidelines.  Adjuvant radiotherapy will be mandatory after breast-conserving surgery, whereas it will be performed according to local guidelines after mastectomy, and it will be administered concomitantly with pertuzumab and trastuzumab FDC SC in subjects who achieve a pCR, and concomitantly with T-DM1 in subjects with residual invasive disease (after anthracycline-based chemotherapy in subjects assigned to receive this treatment).  
  '''Sponsor''': Jules Bordet Institute  
  '''Sponsor''': Jules Bordet Institute  
Line 436: Line 440:
  '''Condition''': HER2-positive Breast Cancer  
  '''Condition''': HER2-positive Breast Cancer  
'''NCTID''': NCT03428217  
'''NCTID''': NCT03428217  
  '''Title''': CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma  
  '''Title''': [[hasTrialTitle::CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma]]
  '''Study Summary''': Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).  
  '''Study Summary''': Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).  
  '''Sponsor''': Calithera Biosciences, Inc  
  '''Sponsor''': Calithera Biosciences, Inc  
Line 446: Line 450:
  '''Condition''': Advanced Renal Cell Carcinoma  
  '''Condition''': Advanced Renal Cell Carcinoma  
'''NCTID''': NCT05462717  
'''NCTID''': NCT05462717  
  '''Title''': Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors  
  '''Title''': [[hasTrialTitle::Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors]]
  '''Study Summary''': The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.  
  '''Study Summary''': The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.  
  '''Sponsor''': Revolution Medicines, Inc.  
  '''Sponsor''': Revolution Medicines, Inc.  
Line 456: Line 460:
  '''Condition''': Non-Small Cell Lung Cancer (NSCLC)  
  '''Condition''': Non-Small Cell Lung Cancer (NSCLC)  
'''NCTID''': NCT03780517  
'''NCTID''': NCT03780517  
  '''Title''': Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors  
  '''Title''': [[hasTrialTitle::Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors]]
  '''Study Summary''': This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.  
  '''Study Summary''': This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.  
  '''Sponsor''': Boston Pharmaceuticals  
  '''Sponsor''': Boston Pharmaceuticals  
Line 466: Line 470:
  '''Condition''': Advanced Nonhaematologic Malignancies  
  '''Condition''': Advanced Nonhaematologic Malignancies  
'''NCTID''': NCT04187404  
'''NCTID''': NCT04187404  
  '''Title''': A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma  
  '''Title''': [[hasTrialTitle::A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma]]
  '''Study Summary''': This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.  
  '''Study Summary''': This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.  
  '''Sponsor''': Enterome  
  '''Sponsor''': Enterome  
Line 476: Line 480:
  '''Condition''': Adrenocortical Carcinoma  
  '''Condition''': Adrenocortical Carcinoma  
'''NCTID''': NCT03941093  
'''NCTID''': NCT03941093  
  '''Title''': Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer  
  '''Title''': [[hasTrialTitle::Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer]]
  '''Study Summary''': This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G  
  '''Study Summary''': This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G  
P) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.  
P) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.  
Line 487: Line 491:
  '''Condition''': Pancreatic Cancer Non-resectable  
  '''Condition''': Pancreatic Cancer Non-resectable  
'''NCTID''': NCT03102320  
'''NCTID''': NCT03102320  
  '''Title''': Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors]]
  '''Study Summary''': The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.  The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.  Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule).  Treatment will continue until disease progression or until another criterion for withdrawal is met. .Efficacy will be measured by evaluating the tumor’s objective response rate. Radiological tumor assessments will be performed at defined time points until the patient’s disease progresses.  Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue will also be collected for mesothelin expression testing and biomarker analyses.  
  '''Study Summary''': The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.  The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.  Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule).  Treatment will continue until disease progression or until another criterion for withdrawal is met. .Efficacy will be measured by evaluating the tumor’s objective response rate. Radiological tumor assessments will be performed at defined time points until the patient’s disease progresses.  Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue will also be collected for mesothelin expression testing and biomarker analyses.  
  '''Sponsor''': Bayer  
  '''Sponsor''': Bayer  
Line 497: Line 501:
  '''Condition''': Neoplasms  
  '''Condition''': Neoplasms  
'''NCTID''': NCT00910091  
'''NCTID''': NCT00910091  
  '''Title''': The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer  
  '''Title''': [[hasTrialTitle::The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer]]
  '''Study Summary''': This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.  
  '''Study Summary''': This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.  
  '''Sponsor''': Ipsen  
  '''Sponsor''': Ipsen  
Line 507: Line 511:
  '''Condition''': Endometrial Cancer  
  '''Condition''': Endometrial Cancer  
'''NCTID''': NCT03377491  
'''NCTID''': NCT03377491  
  '''Title''': Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)  
  '''Title''': [[hasTrialTitle::Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)]]
  '''Study Summary''': Brief Summary:  The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.  
  '''Study Summary''': Brief Summary:  The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.  
  '''Sponsor''': NovoCure Ltd.  
  '''Sponsor''': NovoCure Ltd.  
Line 517: Line 521:
  '''Condition''': Pancreas Adenocarcinoma  
  '''Condition''': Pancreas Adenocarcinoma  
'''NCTID''': NCT02292979  
'''NCTID''': NCT02292979  
  '''Title''': Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.  
  '''Title''': [[hasTrialTitle::Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma]].  
  '''Study Summary''': This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography ) after two cycles of chemotherapy.  
  '''Study Summary''': This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography ) after two cycles of chemotherapy.  
  '''Sponsor''': The Lymphoma Academic Research Organisation  
  '''Sponsor''': The Lymphoma Academic Research Organisation  
Line 527: Line 531:
  '''Condition''': Hodgkin Lymphoma  
  '''Condition''': Hodgkin Lymphoma  
'''NCTID''': NCT03978039  
'''NCTID''': NCT03978039  
  '''Title''': National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group  
  '''Title''': [[hasTrialTitle::National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group]]
  '''Study Summary''': The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas <math display="block">RESOS</math> / French expert network dedicated to the pathology of sarcomas <math display="block">RREPS</math>), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas <math display="block">NETSARC</math>), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.  Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients’ outcomes.  With the financial support of the French National Cancer Institute <math display="block">Institut National du cancer \[INCa</math>).  
  '''Study Summary''': The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas <math display="block">RESOS</math> / French expert network dedicated to the pathology of sarcomas <math display="block">RREPS</math>), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas <math display="block">NETSARC</math>), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.  Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients’ outcomes.  With the financial support of the French National Cancer Institute <math display="block">Institut National du cancer \[INCa</math>).  
  '''Sponsor''': Institut Bergonié  
  '''Sponsor''': Institut Bergonié  
Line 537: Line 541:
  '''Condition''': Sarcoma  
  '''Condition''': Sarcoma  
'''NCTID''': NCT02360579  
'''NCTID''': NCT02360579  
  '''Title''': Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma  
  '''Title''': [[hasTrialTitle::Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma]]
  '''Study Summary''': Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.  
  '''Study Summary''': Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.  
  '''Sponsor''': Iovance Biotherapeutics, Inc.  
  '''Sponsor''': Iovance Biotherapeutics, Inc.  
Line 547: Line 551:
  '''Condition''': Metastatic Melanoma  
  '''Condition''': Metastatic Melanoma  
'''NCTID''': NCT03631706  
'''NCTID''': NCT03631706  
  '''Title''': M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)  
  '''Title''': [[hasTrialTitle::M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)]]
  '''Study Summary''': The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules.  
  '''Study Summary''': The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules.  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
Line 557: Line 561:
  '''Condition''': Non-small Cell Lung Cancer  
  '''Condition''': Non-small Cell Lung Cancer  
'''NCTID''': NCT03906071  
'''NCTID''': NCT03906071  
  '''Title''': Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer  
  '''Title''': [[hasTrialTitle::Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer]]
  '''Study Summary''': This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.  
  '''Study Summary''': This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.  
  '''Sponsor''': Mirati Therapeutics Inc.  
  '''Sponsor''': Mirati Therapeutics Inc.  
Line 567: Line 571:
  '''Condition''': Metastatic Non-Squamous Non-Small Cell Lung Cancer  
  '''Condition''': Metastatic Non-Squamous Non-Small Cell Lung Cancer  
'''NCTID''': NCT03556839  
'''NCTID''': NCT03556839  
  '''Title''': Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix  
  '''Title''': [[hasTrialTitle::Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix]]
  '''Study Summary''': The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity.  The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin).  This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment.  
  '''Study Summary''': The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity.  The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin).  This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment.  
  '''Sponsor''': Grupo Español de Investigación en Cáncer de Ovario  
  '''Sponsor''': Grupo Español de Investigación en Cáncer de Ovario  
Line 577: Line 581:
  '''Condition''': Carcinoma of the Cervix, Stage IVB  
  '''Condition''': Carcinoma of the Cervix, Stage IVB  
'''NCTID''': NCT02794571  
'''NCTID''': NCT02794571  
  '''Title''': Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors  
  '''Title''': [[hasTrialTitle::Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors]]
  '''Study Summary''': This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.  
  '''Study Summary''': This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.  
  '''Sponsor''': Genentech, Inc.  
  '''Sponsor''': Genentech, Inc.  
Line 587: Line 591:
  '''Condition''': Advanced/Metastatic Tumors  
  '''Condition''': Advanced/Metastatic Tumors  
'''NCTID''': NCT01802749  
'''NCTID''': NCT01802749  
  '''Title''': Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer  
  '''Title''': [[hasTrialTitle::Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer]]
  '''Study Summary''': Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.  Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.  This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.  
  '''Study Summary''': Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.  Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.  This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.  
  '''Sponsor''': National Cancer Institute, Naples  
  '''Sponsor''': National Cancer Institute, Naples  
Line 597: Line 601:
  '''Condition''': Recurrent Ovarian Cancer  
  '''Condition''': Recurrent Ovarian Cancer  
'''NCTID''': NCT03395197  
'''NCTID''': NCT03395197  
  '''Title''': Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC  
  '''Title''': [[hasTrialTitle::Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC]]
  '''Study Summary''': This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.  
  '''Study Summary''': This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.  
  '''Sponsor''': Pfizer  
  '''Sponsor''': Pfizer  
Line 607: Line 611:
  '''Condition''': mCRPC  
  '''Condition''': mCRPC  
'''NCTID''': NCT01556490  
'''NCTID''': NCT01556490  
  '''Title''': Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer  
  '''Title''': [[hasTrialTitle::Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer]]
  '''Study Summary''': The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.  
  '''Study Summary''': The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.  
  '''Sponsor''': Boston Scientific Corporation  
  '''Sponsor''': Boston Scientific Corporation  
Line 617: Line 621:
  '''Condition''': Unresectable Hepatocellular Carcinoma  
  '''Condition''': Unresectable Hepatocellular Carcinoma  
'''NCTID''': NCT05323656  
'''NCTID''': NCT05323656  
  '''Title''': A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)  
  '''Title''': [[hasTrialTitle::A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)]]
  '''Study Summary''': The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab.  
  '''Study Summary''': The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab.  
  '''Sponsor''': Calliditas Therapeutics Suisse SA  
  '''Sponsor''': Calliditas Therapeutics Suisse SA  
Line 627: Line 631:
  '''Condition''': Squamous Cell Carcinoma of Head and Neck  
  '''Condition''': Squamous Cell Carcinoma of Head and Neck  
'''NCTID''': NCT03108495  
'''NCTID''': NCT03108495  
  '''Title''': Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma  
  '''Title''': [[hasTrialTitle::Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma]]
  '''Study Summary''': Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma  
  '''Study Summary''': Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma  
  '''Sponsor''': Iovance Biotherapeutics, Inc.  
  '''Sponsor''': Iovance Biotherapeutics, Inc.  
Line 637: Line 641:
  '''Condition''': Cervical Carcinoma  
  '''Condition''': Cervical Carcinoma  
'''NCTID''': NCT02668653  
'''NCTID''': NCT02668653  
  '''Title''': Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)  
  '''Title''': [[hasTrialTitle::Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)]]
  '''Study Summary''': Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).  Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.  
  '''Study Summary''': Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).  Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.  
  '''Sponsor''': Daiichi Sankyo, Inc.  
  '''Sponsor''': Daiichi Sankyo, Inc.  
Line 647: Line 651:
  '''Condition''': Acute Myeloid Leukemia  
  '''Condition''': Acute Myeloid Leukemia  
'''NCTID''': NCT03353753  
'''NCTID''': NCT03353753  
  '''Title''': Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies  
  '''Title''': [[hasTrialTitle::Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies]]
  '''Study Summary''': This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo  
  '''Study Summary''': This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo  
  '''Sponsor''': Deciphera Pharmaceuticals LLC  
  '''Sponsor''': Deciphera Pharmaceuticals LLC  
Line 657: Line 661:
  '''Condition''': Gastrointestinal Stromal Tumors  
  '''Condition''': Gastrointestinal Stromal Tumors  
'''NCTID''': NCT05059262  
'''NCTID''': NCT05059262  
  '''Title''': Study of Vimseltinib for Tenosynovial Giant Cell Tumor  
  '''Title''': [[hasTrialTitle::Study of Vimseltinib for Tenosynovial Giant Cell Tumor]]
  '''Study Summary''': This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.  The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.  
  '''Study Summary''': This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.  The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.  
  '''Sponsor''': Deciphera Pharmaceuticals LLC  
  '''Sponsor''': Deciphera Pharmaceuticals LLC  
Line 667: Line 671:
  '''Condition''': Tenosynovial Giant Cell Tumor  
  '''Condition''': Tenosynovial Giant Cell Tumor  
'''NCTID''': NCT02367794  
'''NCTID''': NCT02367794  
  '''Title''': A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]  
  '''Title''': [[hasTrialTitle::A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]]]  
  '''Study Summary''': This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.  
  '''Study Summary''': This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 677: Line 681:
  '''Condition''': Squamous Non-Small Cell Lung Cancer  
  '''Condition''': Squamous Non-Small Cell Lung Cancer  
'''NCTID''': NCT03872947  
'''NCTID''': NCT03872947  
  '''Title''': A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors]]
  '''Study Summary''': The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Topotecan, and Pegylated liposomal doxorubicin (PLD) for selected advanced solid tumors.  
  '''Study Summary''': The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Topotecan, and Pegylated liposomal doxorubicin (PLD) for selected advanced solid tumors.  
  '''Sponsor''': Toray Industries, Inc  
  '''Sponsor''': Toray Industries, Inc  
Line 687: Line 691:
  '''Condition''': Solid Tumor  
  '''Condition''': Solid Tumor  
'''NCTID''': NCT03465722  
'''NCTID''': NCT03465722  
  '''Title''': (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST  
  '''Title''': [[hasTrialTitle::(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST]]
  '''Study Summary''': This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.  
  '''Study Summary''': This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.  
  '''Sponsor''': Blueprint Medicines Corporation  
  '''Sponsor''': Blueprint Medicines Corporation  
Line 697: Line 701:
  '''Condition''': GIST  
  '''Condition''': GIST  
'''NCTID''': NCT00430365  
'''NCTID''': NCT00430365  
  '''Title''': Maintenance Therapy Using Lenalidomide in Myeloma  
  '''Title''': [[hasTrialTitle::Maintenance Therapy Using Lenalidomide in Myeloma]]
  '''Study Summary''': Maintenance treatment of myeloma.  
  '''Study Summary''': Maintenance treatment of myeloma.  
  '''Sponsor''': University Hospital, Toulouse  
  '''Sponsor''': University Hospital, Toulouse  
Line 707: Line 711:
  '''Condition''': Myeloma  
  '''Condition''': Myeloma  
'''NCTID''': NCT01763164  
'''NCTID''': NCT01763164  
  '''Title''': Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma  
  '''Title''': [[hasTrialTitle::Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma]]
  '''Study Summary''': Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival  
  '''Study Summary''': Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival  
  '''Sponsor''': Pfizer  
  '''Sponsor''': Pfizer  
Line 717: Line 721:
  '''Condition''': Metastatic or Unresectable Cutaneous Melanoma  
  '''Condition''': Metastatic or Unresectable Cutaneous Melanoma  
'''NCTID''': NCT02083653  
'''NCTID''': NCT02083653  
  '''Title''': Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer  
  '''Title''': [[hasTrialTitle::Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer]]
  '''Study Summary''': This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).  
  '''Study Summary''': This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).  
  '''Sponsor''': Symphogen A/S  
  '''Sponsor''': Symphogen A/S  
Line 727: Line 731:
  '''Condition''': Metastatic Colorectal Cancer  
  '''Condition''': Metastatic Colorectal Cancer  
'''NCTID''': NCT01485861  
'''NCTID''': NCT01485861  
  '''Title''': Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy  
  '''Title''': [[hasTrialTitle::Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy]]
  '''Study Summary''': This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of apitolisib administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone.  
  '''Study Summary''': This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of apitolisib administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone.  
  '''Sponsor''': Genentech, Inc.  
  '''Sponsor''': Genentech, Inc.  
Line 737: Line 741:
  '''Condition''': Prostate Cancer  
  '''Condition''': Prostate Cancer  
'''NCTID''': NCT05459129  
'''NCTID''': NCT05459129  
  '''Title''': A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)  
  '''Title''': [[hasTrialTitle::A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)]]
  '''Study Summary''': This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.  
  '''Study Summary''': This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 747: Line 751:
  '''Condition''': Squamous Cell Carcinoma of the Head and Neck  
  '''Condition''': Squamous Cell Carcinoma of the Head and Neck  
'''NCTID''': NCT01739764  
'''NCTID''': NCT01739764  
  '''Title''': An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol  
  '''Title''': [[hasTrialTitle::An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol]]
  '''Study Summary''': This open-label, multicenter, non-randomized study provided continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol’s criteria for disease progression, or were treated beyond progression and were still deriving clinical benefit (as assessed by investigator), and may have therefore potentially benefited from continued treatment with vemurafenib. Participants received treatment with oral vemurafenib at 960 milligrams (mg) twice daily (BID), 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol. Treatment continued until progression of disease or as long as the participant was deriving clinical benefit, as judged by the investigator (case-by-case decision with approval of the Medical Monitor), death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the Sponsor to terminate the study, whichever occurred first.  
  '''Study Summary''': This open-label, multicenter, non-randomized study provided continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol’s criteria for disease progression, or were treated beyond progression and were still deriving clinical benefit (as assessed by investigator), and may have therefore potentially benefited from continued treatment with vemurafenib. Participants received treatment with oral vemurafenib at 960 milligrams (mg) twice daily (BID), 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol. Treatment continued until progression of disease or as long as the participant was deriving clinical benefit, as judged by the investigator (case-by-case decision with approval of the Medical Monitor), death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the Sponsor to terminate the study, whichever occurred first.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 757: Line 761:
  '''Condition''': Neoplasms  
  '''Condition''': Neoplasms  
'''NCTID''': NCT04921553  
'''NCTID''': NCT04921553  
  '''Title''': Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)  
  '''Title''': [[hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)]]
  '''Study Summary''': This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion.  This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.  
  '''Study Summary''': This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion.  This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.  
  '''Sponsor''': Centre Leon Berard  
  '''Sponsor''': Centre Leon Berard  
Line 767: Line 771:
  '''Condition''': Cancer  
  '''Condition''': Cancer  
'''NCTID''': NCT01909453  
'''NCTID''': NCT01909453  
  '''Title''': Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma  
  '''Title''': [[hasTrialTitle::Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma]]
  '''Study Summary''': This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized.  Part 1:  Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms:  # LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm) # LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or # vemurafenib 960 mg BID (denoted as vemurafenib arm)  Part 2:  Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms:  # LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or # LGX818 300 mg QD monotherapy (denoted as LGX818 arm)  
  '''Study Summary''': This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized.  Part 1:  Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms:  # LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm) # LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or # vemurafenib 960 mg BID (denoted as vemurafenib arm)  Part 2:  Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms:  # LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or # LGX818 300 mg QD monotherapy (denoted as LGX818 arm)  
  '''Sponsor''': Pfizer  
  '''Sponsor''': Pfizer  
Line 777: Line 781:
  '''Condition''': Melanoma  
  '''Condition''': Melanoma  
'''NCTID''': NCT05330429  
'''NCTID''': NCT05330429  
  '''Title''': Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)  
  '''Title''': [[hasTrialTitle::Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)]]
  '''Study Summary''': The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).  The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).  
  '''Study Summary''': The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).  The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).  
  '''Sponsor''': Gilead Sciences  
  '''Sponsor''': Gilead Sciences  
Line 787: Line 791:
  '''Condition''': Metastatic Colorectal Cancer  
  '''Condition''': Metastatic Colorectal Cancer  
'''NCTID''': NCT01261429  
'''NCTID''': NCT01261429  
  '''Title''': Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)  
  '''Title''': [[hasTrialTitle::Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)]]
  '''Study Summary''': The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT) who cannot be treated by surgery.  The primary objective of the study will be to determine the efficacy of 12 weeks (3 months) of nilotinib treatment as measured by the non progression rate (Complete response + Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours - RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery.  this study is an international, multicentre, non-randomized, open-label phase II clinical trial with a Bayesian design.  A maximum sample size of 50 patients will be included in the study  
  '''Study Summary''': The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT) who cannot be treated by surgery.  The primary objective of the study will be to determine the efficacy of 12 weeks (3 months) of nilotinib treatment as measured by the non progression rate (Complete response + Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours - RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery.  this study is an international, multicentre, non-randomized, open-label phase II clinical trial with a Bayesian design.  A maximum sample size of 50 patients will be included in the study  
  '''Sponsor''': Centre Leon Berard  
  '''Sponsor''': Centre Leon Berard  
Line 797: Line 801:
  '''Condition''': Pigmented Villonodular Synovitis  
  '''Condition''': Pigmented Villonodular Synovitis  
'''NCTID''': NCT01743469  
'''NCTID''': NCT01743469  
  '''Title''': A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers  
  '''Title''': [[hasTrialTitle::A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers]]
  '''Study Summary''': This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who had progressed after standard therapies.  
  '''Study Summary''': This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who had progressed after standard therapies.  
  '''Sponsor''': Ipsen  
  '''Sponsor''': Ipsen  
Line 807: Line 811:
  '''Condition''': Advanced or Metastatic Hepatocellular Cancer  
  '''Condition''': Advanced or Metastatic Hepatocellular Cancer  
'''NCTID''': NCT03850535  
'''NCTID''': NCT03850535  
  '''Title''': A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission  
  '''Title''': [[hasTrialTitle::A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission]]
  '''Study Summary''': This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine and daunorubicin in induction, in combination with cytarabine in consolidation, and as a single agent in maintenance for treating participants with acute myeloid leukemia (AML).  
  '''Study Summary''': This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine and daunorubicin in induction, in combination with cytarabine in consolidation, and as a single agent in maintenance for treating participants with acute myeloid leukemia (AML).  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 817: Line 821:
  '''Condition''': Acute Myeloid Leukemia  
  '''Condition''': Acute Myeloid Leukemia  
'''NCTID''': NCT02428842  
'''NCTID''': NCT02428842  
  '''Title''': Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)  
  '''Title''': [[hasTrialTitle::Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)]]
  '''Study Summary''': Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.  
  '''Study Summary''': Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.  
  '''Sponsor''': Institut Curie  
  '''Sponsor''': Institut Curie  
Line 827: Line 831:
  '''Condition''': Cervical Cancer  
  '''Condition''': Cervical Cancer  
'''NCTID''': NCT01991210  
'''NCTID''': NCT01991210  
  '''Title''': A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)  
  '''Title''': [[hasTrialTitle::A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)]]
  '''Study Summary''': This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram (mg/kg) intravenously (IV) every 3 weeks or PLD 40 milligrams per meter-squared (mg/m^2) IV every 4 weeks.  
  '''Study Summary''': This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram (mg/kg) intravenously (IV) every 3 weeks or PLD 40 milligrams per meter-squared (mg/m^2) IV every 4 weeks.  
  '''Sponsor''': Genentech, Inc.  
  '''Sponsor''': Genentech, Inc.  
Line 837: Line 841:
  '''Condition''': Ovarian Cancer  
  '''Condition''': Ovarian Cancer  
'''NCTID''': NCT03970746  
'''NCTID''': NCT03970746  
  '''Title''': Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC''lung01 Cancer Vaccine in NSCLC  
  '''Title''': [[hasTrialTitle::Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC''lung01 Cancer Vaccine in NSCLC]]
  '''Study Summary''': PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer.  
  '''Study Summary''': PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer.  
  '''Sponsor''': PDC''line Pharma SAS  
  '''Sponsor''': PDC''line Pharma SAS  
Line 847: Line 851:
  '''Condition''': Non Small Cell Lung Cancer  
  '''Condition''': Non Small Cell Lung Cancer  
'''NCTID''': NCT04246489  
'''NCTID''': NCT04246489  
  '''Title''': Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer  
  '''Title''': [[hasTrialTitle::Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer]]
  '''Study Summary''': The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.  
  '''Study Summary''': The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
Line 857: Line 861:
  '''Condition''': Uterine Cervical Neoplasms  
  '''Condition''': Uterine Cervical Neoplasms  
'''NCTID''': NCT00924989  
'''NCTID''': NCT00924989  
  '''Title''': A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma  
  '''Title''': [[hasTrialTitle::A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma]]
  '''Study Summary''': A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens  
  '''Study Summary''': A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens  
  '''Sponsor''': Astellas Pharma Inc  
  '''Sponsor''': Astellas Pharma Inc  
Line 867: Line 871:
  '''Condition''': Adrenocortical Carcinoma  
  '''Condition''': Adrenocortical Carcinoma  
'''NCTID''': NCT02348489  
'''NCTID''': NCT02348489  
  '''Title''': SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction  
  '''Title''': [[hasTrialTitle::SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction]]
  '''Study Summary''': To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.  
  '''Study Summary''': To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.  
  '''Sponsor''': Astex Pharmaceuticals, Inc.  
  '''Sponsor''': Astex Pharmaceuticals, Inc.  
Line 877: Line 881:
  '''Condition''': Leukemia, Myeloid, Acute  
  '''Condition''': Leukemia, Myeloid, Acute  
'''NCTID''': NCT04892173  
'''NCTID''': NCT04892173  
  '''Title''': NBTXR3 With or Without Cetuximab in LA-HNSCC  
  '''Title''': [[hasTrialTitle::NBTXR3 With or Without Cetuximab in LA-HNSCC]]
  '''Study Summary''': This is a global, open-label, randomized, 2-arm, Investigator’s choice Phase 3 (Pivotal Stage) study to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.  
  '''Study Summary''': This is a global, open-label, randomized, 2-arm, Investigator’s choice Phase 3 (Pivotal Stage) study to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.  
  '''Sponsor''': Nanobiotix  
  '''Sponsor''': Nanobiotix  
Line 887: Line 891:
  '''Condition''': Locally Advanced Head and Neck Squamous Cell Carcinoma  
  '''Condition''': Locally Advanced Head and Neck Squamous Cell Carcinoma  
'''NCTID''': NCT03945773  
'''NCTID''': NCT03945773  
  '''Title''': Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors  
  '''Title''': [[hasTrialTitle::Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors]]
  '''Study Summary''': The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.  
  '''Study Summary''': The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.  
  '''Sponsor''': Ipsen  
  '''Sponsor''': Ipsen  
Line 897: Line 901:
  '''Condition''': Locally Advanced or Metastatic Renal Cell Carcinoma  
  '''Condition''': Locally Advanced or Metastatic Renal Cell Carcinoma  
'''NCTID''': NCT05389462  
'''NCTID''': NCT05389462  
  '''Title''': A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors  
  '''Title''': [[hasTrialTitle::A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors]]
  '''Study Summary''': The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.  
  '''Study Summary''': The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.  
  '''Sponsor''': ADC Therapeutics S.A.  
  '''Sponsor''': ADC Therapeutics S.A.  
Line 907: Line 911:
  '''Condition''': Advanced Solid Tumors  
  '''Condition''': Advanced Solid Tumors  
'''NCTID''': NCT01122472  
'''NCTID''': NCT01122472  
  '''Title''': Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP  
  '''Title''': [[hasTrialTitle::Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP]]
  '''Study Summary''': This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to explore the effect of maintenance therapy with lenalidomide versus placebo on progression-free survival (PFS) in patients treated with R-CHOP responding to induction therapy  For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs 73.6%), is considered clinically relevant.  
  '''Study Summary''': This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to explore the effect of maintenance therapy with lenalidomide versus placebo on progression-free survival (PFS) in patients treated with R-CHOP responding to induction therapy  For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs 73.6%), is considered clinically relevant.  
  '''Sponsor''': The Lymphoma Academic Research Organisation  
  '''Sponsor''': The Lymphoma Academic Research Organisation  
Line 917: Line 921:
  '''Condition''': Lymphoma  
  '''Condition''': Lymphoma  
'''NCTID''': NCT03134638  
'''NCTID''': NCT03134638  
  '''Title''': A Study of SY-1365 in Adult Patients With Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::A Study of SY-1365 in Adult Patients With Advanced Solid Tumors]]
  '''Study Summary''': This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2.  Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.  
  '''Study Summary''': This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2.  Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.  
  '''Sponsor''': Syros Pharmaceuticals  
  '''Sponsor''': Syros Pharmaceuticals  
Line 927: Line 931:
  '''Condition''': Advanced Solid Tumors  
  '''Condition''': Advanced Solid Tumors  
'''NCTID''': NCT04887831  
'''NCTID''': NCT04887831  
  '''Title''': Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab  
  '''Title''': [[hasTrialTitle::Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab]]
  '''Study Summary''': This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.  
  '''Study Summary''': This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.  
  '''Sponsor''': G1 Therapeutics, Inc.  
  '''Sponsor''': G1 Therapeutics, Inc.  
Line 937: Line 941:
  '''Condition''': Urothelial Carcinoma  
  '''Condition''': Urothelial Carcinoma  
'''NCTID''': NCT01373710  
'''NCTID''': NCT01373710  
  '''Title''': Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis  
  '''Title''': [[hasTrialTitle::Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis]]
  '''Study Summary''': The purpose of this study is:  Phase I: To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route to reach a intra CSF target concentration (30 µg/mL) near the conventional therapeutic concentration and depending on the dose-limiting toxicity (DLT)  Phase II: Determination of antitumor activity trastuzumab when administrated by IT or intra-ventricular in terms of neurological progression-free survival at 2 months  
  '''Study Summary''': The purpose of this study is:  Phase I: To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route to reach a intra CSF target concentration (30 µg/mL) near the conventional therapeutic concentration and depending on the dose-limiting toxicity (DLT)  Phase II: Determination of antitumor activity trastuzumab when administrated by IT or intra-ventricular in terms of neurological progression-free survival at 2 months  
  '''Sponsor''': Institut Curie  
  '''Sponsor''': Institut Curie  
Line 947: Line 951:
  '''Condition''': Metastatic Breast Cancer  
  '''Condition''': Metastatic Breast Cancer  
'''NCTID''': NCT03767348  
'''NCTID''': NCT03767348  
  '''Title''': Study of RP1 Monotherapy and RP1 in Combination With Nivolumab  
  '''Title''': [[hasTrialTitle::Study of RP1 Monotherapy and RP1 in Combination With Nivolumab]]
  '''Study Summary''': RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.  
  '''Study Summary''': RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.  
  '''Sponsor''': Replimune Inc.  
  '''Sponsor''': Replimune Inc.  
Line 957: Line 961:
  '''Condition''': Cancer  
  '''Condition''': Cancer  
'''NCTID''': NCT05329766  
'''NCTID''': NCT05329766  
  '''Title''': A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies  
  '''Title''': [[hasTrialTitle::A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies]]
  '''Study Summary''': This is a Phase 2, open-label, parallel 3-cohort, multicenter study to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).  
  '''Study Summary''': This is a Phase 2, open-label, parallel 3-cohort, multicenter study to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).  
  '''Sponsor''': Arcus Biosciences, Inc.  
  '''Sponsor''': Arcus Biosciences, Inc.  
Line 967: Line 971:
  '''Condition''': Gastrointestinal Tract Malignancies  
  '''Condition''': Gastrointestinal Tract Malignancies  
'''NCTID''': NCT02420821  
'''NCTID''': NCT02420821  
  '''Title''': A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)  
  '''Title''': [[hasTrialTitle::A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)]]
  '''Study Summary''': This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.  
  '''Study Summary''': This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 977: Line 981:
  '''Condition''': Renal Cell Carcinoma  
  '''Condition''': Renal Cell Carcinoma  
'''NCTID''': NCT00873119  
'''NCTID''': NCT00873119  
  '''Title''': Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary  
  '''Title''': [[hasTrialTitle::Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary]]
  '''Study Summary''': The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.  
  '''Study Summary''': The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.  
  '''Sponsor''': Onxeo  
  '''Sponsor''': Onxeo  
Line 987: Line 991:
  '''Condition''': Carcinoma of Unknown Primary  
  '''Condition''': Carcinoma of Unknown Primary  
'''NCTID''': NCT03436485  
'''NCTID''': NCT03436485  
  '''Title''': Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer  
  '''Title''': [[hasTrialTitle::Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer]]
  '''Study Summary''': The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.  
  '''Study Summary''': The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.  
  '''Sponsor''': Orion Corporation, Orion Pharma  
  '''Sponsor''': Orion Corporation, Orion Pharma  
Line 997: Line 1,001:
  '''Condition''': Prostate Cancer Metastatic  
  '''Condition''': Prostate Cancer Metastatic  
'''NCTID''': NCT01997333  
'''NCTID''': NCT01997333  
  '''Title''': Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer  
  '''Title''': [[hasTrialTitle::Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer]]
  '''Study Summary''': The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. The study will also further characterize the safety of CDX-011 treatment in this patient population.  
  '''Study Summary''': The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. The study will also further characterize the safety of CDX-011 treatment in this patient population.  
  '''Sponsor''': Celldex Therapeutics  
  '''Sponsor''': Celldex Therapeutics  
Line 1,007: Line 1,011:
  '''Condition''': Metastatic gpNMB Over-expressing Triple Negative Breast Cancer  
  '''Condition''': Metastatic gpNMB Over-expressing Triple Negative Breast Cancer  
'''NCTID''': NCT05099172  
'''NCTID''': NCT05099172  
  '''Title''': First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)  
  '''Title''': [[hasTrialTitle::First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)]]
  '''Study Summary''': Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.  Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer.  Several EGFR and/or HER2 mutations exist in the cancer cells. Two mutations observed in NSCLC are called EGFR- or HER2exon20ins and EGFR C797X. The study treatment, BAY2927088, works by blocking the mutated EGFR protein and also its ex20ins version which are present in NSCLC. It is also believed to work against HER2 and HER2ex20ins mutations. Researchers think this may help stop the further spread of NSCLC cancer.  This is the first time that researchers will study BAY2927088 in humans. In this study, the researchers want to learn more about using BAY2927088 in participants who have NSCLC with EGFR and/or HER2 mutations including EGFRex20ins and/or HER2ex20ins mutations.  The main aims of this study are to find for BAY2927088  * how safe BAY2927088 is * how it affects the body (also referred to as tolerability) * how BAY2927088 moves into, through and out of the body * the maximum amount of BAY2927088 that the participants can take without too many side effects.  The researchers will also study the action of BAY2927088 against the cancer. The study will have three parts: Dose Escalation, Backfill, and Dose Expansion. Each participant of the first, so called dose escalation part, will be assigned to one of specific sequential dose groups for BAY2927088. The amount of BAY2927088 that is given increases stepwise from one group to the next.  The second may be initiated at any dose that has already been tested during the first part and found to be safe and to have either reached a predicted efficacious exposure range or to have induced an objective response. The first part and second part will run concurrently.  The participants of the third, so called dose expansion part, will receive the most appropriate dose of BAY2927088 found in the first and second parts. The third part may be initiated in parallel with the first and second part based on emerging data.  During the study, the participants will take the study treatment in 3 week periods called “cycles”. They will in general take BAY2927088 once daily until their cancer gets worse, until they have medical problems, until they leave the study or until the study is terminated. Participants will have around 5 visits in each cycle.  During the study, the study team will:  * take blood and urine samples * take regular CT or MRI scans to check if the participants’ cancer has gotten better or worse * check the participants’ overall health and heart health * ask the participants questions about how they are feeling and what adverse events they are having.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.  
  '''Study Summary''': Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.  Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer.  Several EGFR and/or HER2 mutations exist in the cancer cells. Two mutations observed in NSCLC are called EGFR- or HER2exon20ins and EGFR C797X. The study treatment, BAY2927088, works by blocking the mutated EGFR protein and also its ex20ins version which are present in NSCLC. It is also believed to work against HER2 and HER2ex20ins mutations. Researchers think this may help stop the further spread of NSCLC cancer.  This is the first time that researchers will study BAY2927088 in humans. In this study, the researchers want to learn more about using BAY2927088 in participants who have NSCLC with EGFR and/or HER2 mutations including EGFRex20ins and/or HER2ex20ins mutations.  The main aims of this study are to find for BAY2927088  * how safe BAY2927088 is * how it affects the body (also referred to as tolerability) * how BAY2927088 moves into, through and out of the body * the maximum amount of BAY2927088 that the participants can take without too many side effects.  The researchers will also study the action of BAY2927088 against the cancer. The study will have three parts: Dose Escalation, Backfill, and Dose Expansion. Each participant of the first, so called dose escalation part, will be assigned to one of specific sequential dose groups for BAY2927088. The amount of BAY2927088 that is given increases stepwise from one group to the next.  The second may be initiated at any dose that has already been tested during the first part and found to be safe and to have either reached a predicted efficacious exposure range or to have induced an objective response. The first part and second part will run concurrently.  The participants of the third, so called dose expansion part, will receive the most appropriate dose of BAY2927088 found in the first and second parts. The third part may be initiated in parallel with the first and second part based on emerging data.  During the study, the participants will take the study treatment in 3 week periods called “cycles”. They will in general take BAY2927088 once daily until their cancer gets worse, until they have medical problems, until they leave the study or until the study is terminated. Participants will have around 5 visits in each cycle.  During the study, the study team will:  * take blood and urine samples * take regular CT or MRI scans to check if the participants’ cancer has gotten better or worse * check the participants’ overall health and heart health * ask the participants questions about how they are feeling and what adverse events they are having.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.  
  '''Sponsor''': Bayer  
  '''Sponsor''': Bayer  
Line 1,017: Line 1,021:
  '''Condition''': Advanced Non-small Cell Lung Cancer  
  '''Condition''': Advanced Non-small Cell Lung Cancer  
'''NCTID''': NCT03063762  
'''NCTID''': NCT03063762  
  '''Title''': Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)  
  '''Title''': [[hasTrialTitle::Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)]]
  '''Study Summary''': This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part.  
  '''Study Summary''': This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 1,027: Line 1,031:
  '''Condition''': Renal Cell Carcinoma  
  '''Condition''': Renal Cell Carcinoma  
'''NCTID''': NCT02678572  
'''NCTID''': NCT02678572  
  '''Title''': Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma  
  '''Title''': [[hasTrialTitle::Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma]]
  '''Study Summary''': This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.  
  '''Study Summary''': This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.  
  '''Sponsor''': Delcath Systems Inc.  
  '''Sponsor''': Delcath Systems Inc.  
Line 1,037: Line 1,041:
  '''Condition''': Melanoma, Ocular  
  '''Condition''': Melanoma, Ocular  
'''NCTID''': NCT02541604  
'''NCTID''': NCT02541604  
  '''Title''': A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors  
  '''Title''': [[hasTrialTitle::A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors]]
  '''Study Summary''': This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.  
  '''Study Summary''': This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 1,047: Line 1,051:
  '''Condition''': Solid Tumor  
  '''Condition''': Solid Tumor  
'''NCTID''': NCT01772004  
'''NCTID''': NCT01772004  
  '''Title''': Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)  
  '''Title''': [[hasTrialTitle::Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)]]
  '''Study Summary''': This is a Phase 1, open-label, dose-escalation trial of avelumab <math display="block">antibody targeting programmed death ligand 1 (anti PD-L1)</math> with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts.  Active cohorts: Escalation revised dosing regimen cohort.  Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .  
  '''Study Summary''': This is a Phase 1, open-label, dose-escalation trial of avelumab <math display="block">antibody targeting programmed death ligand 1 (anti PD-L1)</math> with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts.  Active cohorts: Escalation revised dosing regimen cohort.  Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
  '''Sponsor''': EMD Serono Research &amp; Development Institute, Inc.  
Line 1,057: Line 1,061:
  '''Condition''': Solid Tumors  
  '''Condition''': Solid Tumors  
'''NCTID''': NCT02629692  
'''NCTID''': NCT02629692  
  '''Title''': Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies  
  '''Title''': [[hasTrialTitle::Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies]]
  '''Study Summary''': Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML  
  '''Study Summary''': Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML  
  '''Sponsor''': Sun Pharma Advanced Research Company Limited  
  '''Sponsor''': Sun Pharma Advanced Research Company Limited  
Line 1,067: Line 1,071:
  '''Condition''': Healthy (For Part A)  
  '''Condition''': Healthy (For Part A)  
'''NCTID''': NCT03525392  
'''NCTID''': NCT03525392  
  '''Title''': Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.  
  '''Title''': [[hasTrialTitle::Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1]].  
  '''Study Summary''': This study was being conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1). This study was a first administration of a radioactive drug called 177Lu-3BP-227 to patients under controlled conditions of a clinical study. The purpose of this study is to evaluate how safe this investigational drug is as well to verify how well it is tolerated by patients after several intravenous administrations. In addition, the effect of the study drug on tumoral lesions and how it distributes throughout the body and at which rate it is removed from the body was evaluated. Since 177Lu-3BP-227 is a radio-labelled drug, it will also be measured how the emitted radiation is distributed throughout the body (dosimetry).  The study consisted of a phase I dose escalation part. The study originally planned to include a phase II study however due to early termination (not due to safety concerns) the study did not progress to phase II and was stopped during phase I. For the phase I dose escalation part, it was anticipated that approximately 30 subjects will be included, in up to six escalation steps. No expansion cohorts were implemented.  
  '''Study Summary''': This study was being conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1). This study was a first administration of a radioactive drug called 177Lu-3BP-227 to patients under controlled conditions of a clinical study. The purpose of this study is to evaluate how safe this investigational drug is as well to verify how well it is tolerated by patients after several intravenous administrations. In addition, the effect of the study drug on tumoral lesions and how it distributes throughout the body and at which rate it is removed from the body was evaluated. Since 177Lu-3BP-227 is a radio-labelled drug, it will also be measured how the emitted radiation is distributed throughout the body (dosimetry).  The study consisted of a phase I dose escalation part. The study originally planned to include a phase II study however due to early termination (not due to safety concerns) the study did not progress to phase II and was stopped during phase I. For the phase I dose escalation part, it was anticipated that approximately 30 subjects will be included, in up to six escalation steps. No expansion cohorts were implemented.  
  '''Sponsor''': Ipsen  
  '''Sponsor''': Ipsen  
Line 1,077: Line 1,081:
  '''Condition''': Pancreatic Ductal Adenocarcinoma  
  '''Condition''': Pancreatic Ductal Adenocarcinoma  
'''NCTID''': NCT02052778  
'''NCTID''': NCT02052778  
  '''Title''': A Study of TAS-120 in Patients With Advanced Solid Tumors  
  '''Title''': [[hasTrialTitle::A Study of TAS-120 in Patients With Advanced Solid Tumors]]
  '''Study Summary''': This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of futibatinib in patients with advanced solid tumors with and without genomic FGF/FGFR abnormalities. The study will be conducted in 3 parts:  # Dose escalation portion to determine the MTD and/ or RP2D of futibatinib. # Phase 1 expansion portion to further evaluate the safety and efficacy of futibatinib in patients with tumors harboring FGF/FGFR aberrations, including patients with cholangiocarcinoma (CCA), primary CNS tumors, urothelial carcinoma, breast cancer, gastric cancer. # Phase 2 study portion to confirm ORR of futibatinib in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).  
  '''Study Summary''': This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of futibatinib in patients with advanced solid tumors with and without genomic FGF/FGFR abnormalities. The study will be conducted in 3 parts:  # Dose escalation portion to determine the MTD and/ or RP2D of futibatinib. # Phase 1 expansion portion to further evaluate the safety and efficacy of futibatinib in patients with tumors harboring FGF/FGFR aberrations, including patients with cholangiocarcinoma (CCA), primary CNS tumors, urothelial carcinoma, breast cancer, gastric cancer. # Phase 2 study portion to confirm ORR of futibatinib in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).  
  '''Sponsor''': Taiho Oncology, Inc.  
  '''Sponsor''': Taiho Oncology, Inc.  
Line 1,087: Line 1,091:
  '''Condition''': Cholangiocarcinoma  
  '''Condition''': Cholangiocarcinoma  
'''NCTID''': NCT03009058  
'''NCTID''': NCT03009058  
  '''Title''': Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer  
  '''Title''': [[hasTrialTitle::Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer]]
  '''Study Summary''': During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient’s specific tumour type.  The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.  
  '''Study Summary''': During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient’s specific tumour type.  The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.  
  '''Sponsor''': Immodulon Therapeutics Ltd  
  '''Sponsor''': Immodulon Therapeutics Ltd  
Line 1,097: Line 1,101:
  '''Condition''': Metastatic Cancer  
  '''Condition''': Metastatic Cancer  
'''NCTID''': NCT04628494  
'''NCTID''': NCT04628494  
  '''Title''': A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL  
  '''Title''': [[hasTrialTitle::A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL]]
  '''Study Summary''': The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of epcoritamab has already been studied in previous studies in humans, the main purpose of this study is to evaluate efficacy. To evaluate this, half of the participants who are eligible will receive epcoritamab and the other half will receive a pre-specified investigator’s choice of chemotherapy. Epcoritamab will be studied in R/R DLBCL participants who did not respond to a previous autologous stem cell transplant (ASCT) or do not meet the criteria for ASCT  
  '''Study Summary''': The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of epcoritamab has already been studied in previous studies in humans, the main purpose of this study is to evaluate efficacy. To evaluate this, half of the participants who are eligible will receive epcoritamab and the other half will receive a pre-specified investigator’s choice of chemotherapy. Epcoritamab will be studied in R/R DLBCL participants who did not respond to a previous autologous stem cell transplant (ASCT) or do not meet the criteria for ASCT  
  '''Sponsor''': Genmab  
  '''Sponsor''': Genmab  
Line 1,107: Line 1,111:
  '''Condition''': Diffuse Large B-cell Lymphoma  
  '''Condition''': Diffuse Large B-cell Lymphoma  
'''NCTID''': NCT03793478  
'''NCTID''': NCT03793478  
  '''Title''': Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood  
  '''Title''': [[hasTrialTitle::Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood]]
  '''Study Summary''': Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.  
  '''Study Summary''': Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.  
  '''Sponsor''': Daiichi Sankyo, Inc.  
  '''Sponsor''': Daiichi Sankyo, Inc.  
Line 1,117: Line 1,121:
  '''Condition''': Acute Myeloid Leukemia  
  '''Condition''': Acute Myeloid Leukemia  
'''NCTID''': NCT01303094  
'''NCTID''': NCT01303094  
  '''Title''': Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma  
  '''Title''': [[hasTrialTitle::Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma]]
  '''Study Summary''': This randomization discontinuation trial will allow for concomitant evaluation of the following:  * Side effects and benefits of immediate continuation of Trabectedin after the sixth cycle * Side effects and benefits of a drug holiday  
  '''Study Summary''': This randomization discontinuation trial will allow for concomitant evaluation of the following:  * Side effects and benefits of immediate continuation of Trabectedin after the sixth cycle * Side effects and benefits of a drug holiday  
  '''Sponsor''': Centre Oscar Lambret  
  '''Sponsor''': Centre Oscar Lambret  
Line 1,127: Line 1,131:
  '''Condition''': Soft Tissue Sarcoma  
  '''Condition''': Soft Tissue Sarcoma  
'''NCTID''': NCT03306394  
'''NCTID''': NCT03306394  
  '''Title''': A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).  
  '''Title''': [[hasTrialTitle::A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic)]].  
  '''Study Summary''': The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).  Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor’s prescription or can be accessed from another source or Sponsor decision.  
  '''Study Summary''': The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).  Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor’s prescription or can be accessed from another source or Sponsor decision.  
  '''Sponsor''': Institut de Recherches Internationales Servier  
  '''Sponsor''': Institut de Recherches Internationales Servier  
Line 1,137: Line 1,141:
  '''Condition''': Metastatic Colorectal Cancer  
  '''Condition''': Metastatic Colorectal Cancer  
'''NCTID''': NCT04774718  
'''NCTID''': NCT04774718  
  '''Title''': A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors  
  '''Title''': [[hasTrialTitle::A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors]]
  '''Study Summary''': This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.  
  '''Study Summary''': This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.  
  '''Sponsor''': Hoffmann-La Roche  
  '''Sponsor''': Hoffmann-La Roche  
Line 1,147: Line 1,151:
  '''Condition''': ALK Fusion-positive Solid or CNS Tumors  
  '''Condition''': ALK Fusion-positive Solid or CNS Tumors  
'''NCTID''': NCT03786094  
'''NCTID''': NCT03786094  
  '''Title''': Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer  
  '''Title''': [[hasTrialTitle::Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer]]
  '''Study Summary''': This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.  
  '''Study Summary''': This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.  
  '''Sponsor''': Spexis AG  
  '''Sponsor''': Spexis AG  
Line 1,157: Line 1,161:
  '''Condition''': Metastatic Breast Cancer  
  '''Condition''': Metastatic Breast Cancer  
'''NCTID''': NCT01569295  
'''NCTID''': NCT01569295  
  '''Title''': Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )  
  '''Title''': [[hasTrialTitle::Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela)]]
  '''Study Summary''': The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)  
  '''Study Summary''': The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)  
  '''Sponsor''': Gilead Sciences  
  '''Sponsor''': Gilead Sciences  
Line 1,167: Line 1,171:
  '''Condition''': Chronic Lymphocytic Leukemia  
  '''Condition''': Chronic Lymphocytic Leukemia  
'''NCTID''': NCT05183984  
'''NCTID''': NCT05183984  
  '''Title''': Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer  
  '''Title''': [[hasTrialTitle::Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovarian Cancer]]
  '''Study Summary''': Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.  
  '''Study Summary''': Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.  
  '''Sponsor''': ARCAGY/ GINECO GROUP  
  '''Sponsor''': ARCAGY/ GINECO GROUP  
Line 1,177: Line 1,181:
  '''Condition''': Ovarian Cancer  
  '''Condition''': Ovarian Cancer  
'''NCTID''': NCT05587296  
'''NCTID''': NCT05587296  
  '''Title''': A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer  
  '''Title''': [[hasTrialTitle::A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer]]
  '''Study Summary''': Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy.  VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer.  It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.  The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.  The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it.  To answer this, the doctors will ask the participants to record information about their hot flashes before treatment start and at certain time points during the treatment in an electronic diary. The researchers will then assess possible average changes in number and severity of hot flashes after 4 and 12 weeks of treatment.  To see how safe elinzanetant is compared to placebo. The study will collect information about the number of participants who have medical problems after taking treatment.  The study participants will be randomly (by chance) assigned to 2 treatment groups, A and B. The participants from treatment group A will take elinzanetant. The participants from treatment group B will start with placebo and then switch to elinzanetant.  All participants will continue taking the anti-cancer therapy they have been using when entering the study.  Dependent on the treatment group, the participants will either take elinzanetant or placebo as capsules by mouth once a day. After 12 weeks, the participants who have initially received placebo will switch to take elinzanetant for the remaining 40 weeks.  Each participant will be in the study for approximately 62 weeks. The treatment duration in the study will be 52 weeks. There will be up to 12 visits to the study site and 6 phone calls in between. Participants who completed the 52 weeks treatment phase, will be offered to continue treatment for another 2 years. Visit frequency: every 24 weeks until week 152.  During the study, the participants will:  * record information about their hot flashes * answer questions about their quality of life and other symptoms.  The doctors and their study team will:  * check the participants health and vital signs * take blood and urine samples * examine heart health using electrocardiogram (ECG) * examine pelvic organs like womb or ovaries using a trans vaginal ultrasound scan to see images of these organs * make images of the breast using x-ray (mammogram), a type of radiation that passes through the body to make images of the inside and/or by using ultrasound (if applicable) * check the health of the participant’s cervix (neck of the womb) by taking a small sample of cells (smear test) for an analysis called cervical cytology (if applicable) * take an endometrial biopsy, a small piece of tissue from the lining of the womb (called the endometrium) for analysis. * ask the participants questions about what medicines they are taking and if they are having adverse events.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.  About 4 weeks after the participants take their last treatment, the study doctors and their team will check the participants’ health.  
  '''Study Summary''': Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy.  VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer.  It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.  The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.  The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it.  To answer this, the doctors will ask the participants to record information about their hot flashes before treatment start and at certain time points during the treatment in an electronic diary. The researchers will then assess possible average changes in number and severity of hot flashes after 4 and 12 weeks of treatment.  To see how safe elinzanetant is compared to placebo. The study will collect information about the number of participants who have medical problems after taking treatment.  The study participants will be randomly (by chance) assigned to 2 treatment groups, A and B. The participants from treatment group A will take elinzanetant. The participants from treatment group B will start with placebo and then switch to elinzanetant.  All participants will continue taking the anti-cancer therapy they have been using when entering the study.  Dependent on the treatment group, the participants will either take elinzanetant or placebo as capsules by mouth once a day. After 12 weeks, the participants who have initially received placebo will switch to take elinzanetant for the remaining 40 weeks.  Each participant will be in the study for approximately 62 weeks. The treatment duration in the study will be 52 weeks. There will be up to 12 visits to the study site and 6 phone calls in between. Participants who completed the 52 weeks treatment phase, will be offered to continue treatment for another 2 years. Visit frequency: every 24 weeks until week 152.  During the study, the participants will:  * record information about their hot flashes * answer questions about their quality of life and other symptoms.  The doctors and their study team will:  * check the participants health and vital signs * take blood and urine samples * examine heart health using electrocardiogram (ECG) * examine pelvic organs like womb or ovaries using a trans vaginal ultrasound scan to see images of these organs * make images of the breast using x-ray (mammogram), a type of radiation that passes through the body to make images of the inside and/or by using ultrasound (if applicable) * check the health of the participant’s cervix (neck of the womb) by taking a small sample of cells (smear test) for an analysis called cervical cytology (if applicable) * take an endometrial biopsy, a small piece of tissue from the lining of the womb (called the endometrium) for analysis. * ask the participants questions about what medicines they are taking and if they are having adverse events.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.  About 4 weeks after the participants take their last treatment, the study doctors and their team will check the participants’ health.  
  '''Sponsor''': Bayer  
  '''Sponsor''': Bayer  
Line 1,187: Line 1,191:
  '''Condition''': Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer  
  '''Condition''': Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer  
'''NCTID''': NCT01526928  
'''NCTID''': NCT01526928  
  '''Title''': Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients  
  '''Title''': [[hasTrialTitle::Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients]]
  '''Study Summary''': Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral rociletinib; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral rociletinib; to assess the safety and efficacy of rociletinib in previously treated NSCLC patients known to have the T790M EGFR mutation.  
  '''Study Summary''': Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral rociletinib; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral rociletinib; to assess the safety and efficacy of rociletinib in previously treated NSCLC patients known to have the T790M EGFR mutation.  
  '''Sponsor''': Clovis Oncology, Inc.  
  '''Sponsor''': Clovis Oncology, Inc.  
Line 1,197: Line 1,201:
  '''Condition''': Locally Advanced or Metastatic Non Small Cell Lung Cancer  
  '''Condition''': Locally Advanced or Metastatic Non Small Cell Lung Cancer  
'''NCTID''': NCT03669718  
'''NCTID''': NCT03669718  
  '''Title''': A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC  
  '''Title''': [[hasTrialTitle::A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC]]
  '''Study Summary''': This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.  
  '''Study Summary''': This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.  
  '''Sponsor''': ISA Pharmaceuticals  
  '''Sponsor''': ISA Pharmaceuticals  
Line 1,207: Line 1,211:
  '''Condition''': Squamous Cell Carcinoma of the Oropharynx  
  '''Condition''': Squamous Cell Carcinoma of the Oropharynx  
'''NCTID''': NCT02975934  
'''NCTID''': NCT02975934  
  '''Title''': A Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency  
  '''Title''': [[hasTrialTitle::A Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency]]
  '''Study Summary''': The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician’s choice of abiraterone acetate, enzalutamide, or docetaxel.  
  '''Study Summary''': The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician’s choice of abiraterone acetate, enzalutamide, or docetaxel.  
  '''Sponsor''': pharmaand GmbH  
  '''Sponsor''': pharmaand GmbH  
Line 1,217: Line 1,221:
  '''Condition''': Metastatic Castration Resistant Prostate Cancer  
  '''Condition''': Metastatic Castration Resistant Prostate Cancer  
'''NCTID''': NCT03673501  
'''NCTID''': NCT03673501  
  '''Title''': A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib  
  '''Title''': [[hasTrialTitle::A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib]]
  '''Study Summary''': This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).  
  '''Study Summary''': This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).  
  '''Sponsor''': Deciphera Pharmaceuticals LLC  
  '''Sponsor''': Deciphera Pharmaceuticals LLC  
Line 1,227: Line 1,231:
  '''Condition''': Gastrointestinal Stromal Tumors  
  '''Condition''': Gastrointestinal Stromal Tumors  
'''NCTID''': NCT04050436  
'''NCTID''': NCT04050436  
  '''Title''': Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer  
  '''Title''': [[hasTrialTitle::Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer]]
  '''Study Summary''': To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.  
  '''Study Summary''': To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.  
  '''Sponsor''': Replimune Inc.  
  '''Sponsor''': Replimune Inc.  
Line 1,237: Line 1,241:
  '''Condition''': Cutaneous Squamous Cell Carcinoma  
  '''Condition''': Cutaneous Squamous Cell Carcinoma  
'''NCTID''': NCT05275478  
'''NCTID''': NCT05275478  
  '''Title''': Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors  
  '''Title''': [[hasTrialTitle::Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors]]
  '''Study Summary''': This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.  
  '''Study Summary''': This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.  
  '''Sponsor''': Tango Therapeutics, Inc.  
  '''Sponsor''': Tango Therapeutics, Inc.  
Line 1,247: Line 1,251:
  '''Condition''': Locally Advanced Solid Tumor  
  '''Condition''': Locally Advanced Solid Tumor  
'''NCTID''': NCT00718523  
'''NCTID''': NCT00718523  
  '''Title''': Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer  
  '''Title''': [[hasTrialTitle::Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer]]
  '''Study Summary''': This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (&lt;1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.  
  '''Study Summary''': This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (&lt;1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.  
  '''Sponsor''': Translational Research in Oncology  
  '''Sponsor''': Translational Research in Oncology  
Line 1,257: Line 1,261:
  '''Condition''': Ovarian Neoplasms  
  '''Condition''': Ovarian Neoplasms  
'''NCTID''': NCT01957436  
'''NCTID''': NCT01957436  
  '''Title''': A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer  
  '''Title''': [[hasTrialTitle::A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer]]
  '''Study Summary''': This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.  
  '''Study Summary''': This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.  
  '''Sponsor''': UNICANCER  
  '''Sponsor''': UNICANCER  
Line 1,267: Line 1,271:
  '''Condition''': Metastatic Prostate Cancer  
  '''Condition''': Metastatic Prostate Cancer  
'''NCTID''': NCT04797780  
'''NCTID''': NCT04797780  
  '''Title''': Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome  
  '''Title''': [[hasTrialTitle::Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome]]
  '''Study Summary''': This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.  
  '''Study Summary''': This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.  
  '''Sponsor''': Syros Pharmaceuticals  
  '''Sponsor''': Syros Pharmaceuticals  
Line 1,277: Line 1,281:
  '''Condition''': Myelodysplastic Syndromes  
  '''Condition''': Myelodysplastic Syndromes  
'''NCTID''': NCT01796002  
'''NCTID''': NCT01796002  
  '''Title''': Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma  
  '''Title''': [[hasTrialTitle::Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma]]
  '''Study Summary''': Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).  
  '''Study Summary''': Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).  
  '''Sponsor''': The Lymphoma Academic Research Organisation  
  '''Sponsor''': The Lymphoma Academic Research Organisation  
Line 1,287: Line 1,291:
  '''Condition''': Peripheral T-cell Lymphoma  
  '''Condition''': Peripheral T-cell Lymphoma  
'''NCTID''': NCT02511678  
'''NCTID''': NCT02511678  
  '''Title''': Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases  
  '''Title''': [[hasTrialTitle::Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases]]
  '''Study Summary''': This study will evaluate the efficacy of cryoablation for palliation of painful metastases in participants with metastatic lesions involving bone who have failed, are not candidates for, or are not experiencing adequate pain relief from current pain therapies (for example, radiation, analgesics).  
  '''Study Summary''': This study will evaluate the efficacy of cryoablation for palliation of painful metastases in participants with metastatic lesions involving bone who have failed, are not candidates for, or are not experiencing adequate pain relief from current pain therapies (for example, radiation, analgesics).  
  '''Sponsor''': Boston Scientific Corporation  
  '''Sponsor''': Boston Scientific Corporation  
Line 1,297: Line 1,301:
  '''Condition''': Pain  
  '''Condition''': Pain  
'''NCTID''': NCT05566795  
'''NCTID''': NCT05566795  
  '''Title''': DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)  
  '''Title''': [[hasTrialTitle::DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)]]
  '''Study Summary''': This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.  
  '''Study Summary''': This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.  
  '''Sponsor''': Day One Biopharmaceuticals, Inc.  
  '''Sponsor''': Day One Biopharmaceuticals, Inc.  
Line 1,307: Line 1,311:
  '''Condition''': Low-grade Glioma  
  '''Condition''': Low-grade Glioma  
'''NCTID''': NCT00642395  
'''NCTID''': NCT00642395  
  '''Title''': Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)  
  '''Title''': [[hasTrialTitle::Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)]]
  '''Study Summary''': Intensification with autologous stem cell
  '''Study Summary''': Intensification with autologous stem cell
<span style="display:none">hasTrialTitle::Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy</span>
<span style="display:none">hasTrialTitle::A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC</span>
<span style="display:none">hasTrialTitle::Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL</span>
<span style="display:none">hasTrialTitle::D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma</span>
<span style="display:none">hasTrialTitle::A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</span>
<span style="display:none">hasTrialTitle::Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer</span>
<span style="display:none">hasTrialTitle::Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer</span>
<span style="display:none">hasTrialTitle::A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)</span>
<span style="display:none">hasTrialTitle::A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer</span>
<span style="display:none">hasTrialTitle::A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer</span>
<span style="display:none">hasTrialTitle::A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors</span>
<span style="display:none">hasTrialTitle::Study of ASTX029 in Subjects With Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246</span>
<span style="display:none">hasTrialTitle::Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations</span>
<span style="display:none">hasTrialTitle::A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types</span>
<span style="display:none">hasTrialTitle::Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan &amp; Gemcitabine vs Placebo &amp; Gemcitabine in Metastatic Pancreatic Cancer</span>
<span style="display:none">hasTrialTitle::Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH</span>
<span style="display:none">hasTrialTitle::Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer</span>
<span style="display:none">hasTrialTitle::Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer</span>
<span style="display:none">hasTrialTitle::A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC</span>
<span style="display:none">hasTrialTitle::Futibatinib in Patients With Specific FGFR Aberrations</span>
<span style="display:none">hasTrialTitle::Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor</span>
<span style="display:none">hasTrialTitle::A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors</span>
<span style="display:none">hasTrialTitle::Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors</span>
<span style="display:none">hasTrialTitle::Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma</span>
<span style="display:none">hasTrialTitle::A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma</span>
<span style="display:none">hasTrialTitle::Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen</span>
<span style="display:none">hasTrialTitle::Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer</span>
<span style="display:none">hasTrialTitle::A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)</span>
<span style="display:none">hasTrialTitle::Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations</span>
<span style="display:none">hasTrialTitle::A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer</span>
<span style="display:none">hasTrialTitle::Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas</span>
<span style="display:none">hasTrialTitle::A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)</span>
<span style="display:none">hasTrialTitle::Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</span>
<span style="display:none">hasTrialTitle::Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC</span>
<span style="display:none">hasTrialTitle::A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)</span>
<span style="display:none">hasTrialTitle::A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)</span>
<span style="display:none">hasTrialTitle::A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer</span>
<span style="display:none">hasTrialTitle::Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer</span>
<span style="display:none">hasTrialTitle::De-escalation Adjuvant Chemo in HER2+/ER-ode-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo &amp; Dual HER2 Blockade</span>
<span style="display:none">hasTrialTitle::CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma</span>
<span style="display:none">hasTrialTitle::Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors</span>
<span style="display:none">hasTrialTitle::Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors</span>
<span style="display:none">hasTrialTitle::A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma</span>
<span style="display:none">hasTrialTitle::Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer</span>
<span style="display:none">hasTrialTitle::Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer</span>
<span style="display:none">hasTrialTitle::Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)</span>
<span style="display:none">hasTrialTitle::Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma</span>
<span style="display:none">hasTrialTitle::National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group</span>
<span style="display:none">hasTrialTitle::Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma</span>
<span style="display:none">hasTrialTitle::M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)</span>
<span style="display:none">hasTrialTitle::Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer</span>
<span style="display:none">hasTrialTitle::Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix</span>
<span style="display:none">hasTrialTitle::Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors</span>
<span style="display:none">hasTrialTitle::Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer</span>
<span style="display:none">hasTrialTitle::Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC</span>
<span style="display:none">hasTrialTitle::Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer</span>
<span style="display:none">hasTrialTitle::A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)</span>
<span style="display:none">hasTrialTitle::Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma</span>
<span style="display:none">hasTrialTitle::Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)</span>
<span style="display:none">hasTrialTitle::Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies</span>
<span style="display:none">hasTrialTitle::Study of Vimseltinib for Tenosynovial Giant Cell Tumor</span>
<span style="display:none">hasTrialTitle::A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131</span>
<span style="display:none">hasTrialTitle::A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST</span>
<span style="display:none">hasTrialTitle::Maintenance Therapy Using Lenalidomide in Myeloma</span>
<span style="display:none">hasTrialTitle::Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma</span>
<span style="display:none">hasTrialTitle::Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer</span>
<span style="display:none">hasTrialTitle::Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy</span>
<span style="display:none">hasTrialTitle::A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)</span>
<span style="display:none">hasTrialTitle::An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol</span>
<span style="display:none">hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)</span>
<span style="display:none">hasTrialTitle::Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma</span>
<span style="display:none">hasTrialTitle::Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)</span>
<span style="display:none">hasTrialTitle::Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)</span>
<span style="display:none">hasTrialTitle::A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers</span>
<span style="display:none">hasTrialTitle::A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission</span>
<span style="display:none">hasTrialTitle::Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)</span>
<span style="display:none">hasTrialTitle::A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)</span>
<span style="display:none">hasTrialTitle::Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC''lung01 Cancer Vaccine in NSCLC</span>
<span style="display:none">hasTrialTitle::Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer</span>
<span style="display:none">hasTrialTitle::A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma</span>
<span style="display:none">hasTrialTitle::SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction</span>
<span style="display:none">hasTrialTitle::NBTXR3 With or Without Cetuximab in LA-HNSCC</span>
<span style="display:none">hasTrialTitle::Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors</span>
<span style="display:none">hasTrialTitle::A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors</span>
<span style="display:none">hasTrialTitle::Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP</span>
<span style="display:none">hasTrialTitle::A Study of SY-1365 in Adult Patients With Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab</span>
<span style="display:none">hasTrialTitle::Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis</span>
<span style="display:none">hasTrialTitle::Study of RP1 Monotherapy and RP1 in Combination With Nivolumab</span>
<span style="display:none">hasTrialTitle::A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies</span>
<span style="display:none">hasTrialTitle::A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)</span>
<span style="display:none">hasTrialTitle::Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary</span>
<span style="display:none">hasTrialTitle::Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer</span>
<span style="display:none">hasTrialTitle::Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer</span>
<span style="display:none">hasTrialTitle::First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)</span>
<span style="display:none">hasTrialTitle::Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)</span>
<span style="display:none">hasTrialTitle::Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma</span>
<span style="display:none">hasTrialTitle::Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)</span>
<span style="display:none">hasTrialTitle::Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies</span>
<span style="display:none">hasTrialTitle::Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1</span>
<span style="display:none">hasTrialTitle::A Study of TAS-120 in Patients With Advanced Solid Tumors</span>
<span style="display:none">hasTrialTitle::Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer</span>
<span style="display:none">hasTrialTitle::A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL</span>
<span style="display:none">hasTrialTitle::Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood</span>
<span style="display:none">hasTrialTitle::Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma</span>
<span style="display:none">hasTrialTitle::A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic)</span>
<span style="display:none">hasTrialTitle::A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors</span>
<span style="display:none">hasTrialTitle::Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer</span>
<span style="display:none">hasTrialTitle::Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela)</span>
<span style="display:none">hasTrialTitle::Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovarian Cancer</span>
<span style="display:none">hasTrialTitle::A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer</span>
<span style="display:none">hasTrialTitle::Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients</span>
<span style="display:none">hasTrialTitle::A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC</span>
<span style="display:none">hasTrialTitle::A Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency</span>
<span style="display:none">hasTrialTitle::A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib</span>
<span style="display:none">hasTrialTitle::Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer</span>
<span style="display:none">hasTrialTitle::Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors</span>
<span style="display:none">hasTrialTitle::Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer</span>
<span style="display:none">hasTrialTitle::A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer</span>
<span style="display:none">hasTrialTitle::Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome</span>
<span style="display:none">hasTrialTitle::Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma</span>
<span style="display:none">hasTrialTitle::Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases</span>
<span style="display:none">hasTrialTitle::DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)</span>
<span style="display:none">hasTrialTitle::Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)</span>
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
<span style="display:none">hasCancerType::C50: Breast cancer</span>
<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
<span style="display:none">hasCancerType::unknown</span>
<span style="display:none">isTrial</span>

Latest revision as of 18:34, 14 December 2025

forpatients forproviders forresearchers francecountry Go back to Léon Bérard Center page

Trials: How to participate[edit | edit source]

Contact information: Click here to access.


NCTID: NCT01222767 

Title: Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy 
Study Summary: This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy to determine the antitumor activity of Zalypsis. 
Sponsor: PharmaMar 
Intervention: Zalypsis 
Start Date: 2010-12 
Last Updated: 2021-10-29 
Number of Patients: 17 
Recruitment Status: COMPLETED 
Condition: Ewing’s Sarcoma

NCTID: NCT01798485 

Title: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC 
Study Summary: The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer. 
Sponsor: Synta Pharmaceuticals Corp. 
Intervention: Docetaxel 
Start Date: 2013-04 
Last Updated: 2016-07-01 
Number of Patients: 696 
Recruitment Status: TERMINATED 
Condition: Non-Small-Cell Lung Adenocarcinoma

NCTID: NCT03037385 

Title: Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors 
Study Summary: This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors. 
Sponsor: Hoffmann-La Roche 
Intervention: pralsetinib (BLU-667) 
Start Date: 2017-03-17 
Last Updated: 2023-11-27 
Number of Patients: 589 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: RET-altered Non Small Cell Lung Cancer

NCTID: NCT03336333 

Title: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL 
Study Summary: To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review. 
Sponsor: BeiGene 
Intervention: Zanubrutinib 
Start Date: 2017-10-31 
Last Updated: 2023-11-09 
Number of Patients: 590 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Chronic Lymphocytic Leukemia

NCTID: NCT01882933 

Title: D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma 
Study Summary: A prospective, opened, multicentric, randomised, phase III trial with two arms:  * Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin * Arm B: curative gastrectomy with D1-D2 lymph node dissection  Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology), treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy alone. 
Sponsor: Hospices Civils de Lyon 
Intervention: HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin 
Start Date: 2013-06 
Last Updated: 2023-04-19 
Number of Patients: 367 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Gastric Adenocarcinoma

NCTID: NCT03038100 

Title: A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 
Study Summary: This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery. 
Sponsor: Hoffmann-La Roche 
Intervention: Paclitaxel 
Start Date: 2017-03-08 
Last Updated: 2023-02-17 
Number of Patients: 1301 
Recruitment Status: COMPLETED 
Condition: Ovarian Cancer

NCTID: NCT02500043 

Title: Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer 
Study Summary: The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer. 
Sponsor: Taiho Oncology, Inc. 
Intervention: TAS-102 
Start Date: 2016-02-24 
Last Updated: 2021-09-16 
Number of Patients: 507 
Recruitment Status: COMPLETED 
Condition: Refractory Metastatic Gastric Cancer

NCTID: NCT02947685 

Title: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer 
Study Summary: The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer. 
Sponsor: Alliance Foundation Trials, LLC. 
Intervention: palbociclib 
Start Date: 2017-06-21 
Last Updated: 2023-05-30 
Number of Patients: 496 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: HER-2 Positive Breast Cancer

NCTID: NCT03940703 

Title: A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) 
Study Summary: This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC). 
Sponsor: EMD Serono Research & Development Institute, Inc. 
Intervention: Tepotinib 
Start Date: 2019-09-19 
Last Updated: 2023-08-29 
Number of Patients: 120 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Non-small Cell Lung Cancer

NCTID: NCT01322490 

Title: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer 
Study Summary: The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer. 
Sponsor: Bavarian Nordic 
Intervention: PROSTVAC-V 
Start Date: 2011-11-28 
Last Updated: 2019-09-04 
Number of Patients: 1297 
Recruitment Status: COMPLETED 
Condition: Prostate Cancer Metastatic

NCTID: NCT03493854 

Title: A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer 
Study Summary: This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting. 
Sponsor: Hoffmann-La Roche 
Intervention: Cyclophosphamide 
Start Date: 2018-06-14 
Last Updated: 2023-06-15 
Number of Patients: 500 
Recruitment Status: COMPLETED 
Condition: Early Breast Cancer

NCTID: NCT04704154 

Title: A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors 
Study Summary: Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.  In this trial, the researchers want to learn about regorafenib taken together with nivolumab in a small number of participants with different types of tumors. These include tumors in the head and neck, the esophagus, the pancreas, the brain, and the biliary tract. The biliary tract includes gall bladder and bile ducts.  The trial will include about 200 participants who are at least 18 years old. All of the participants will take 90 mg of regorafenib as a tablet by mouth. The dose of regorafenib can be adjusted up to 120 mg or down to 60 mg by the doctor based on how well a participant tolerates treatment. All of the participants will receive 480 milligrams (mg) of nivolumab through a needle put into a vein (IV infusion).  The participants will take treatments in 4-week periods called cycles. They will take regorafenib once a day for 3 weeks, then stop for 1 week. In each cycle, the participants will receive nivolumab one time. These 4-week cycles will be repeated throughout the trial. The participants can take nivolumab and regorafenib until their cancer gets worse, until they have medical problems, or until they leave the trial. The longest nivolumab can be given is up to 2 years.  During the trial, the doctors will take pictures of the participants’ tumors using CT or MRI and will take blood and urine samples. The doctors will also do physical examinations and check the participants’ heart health using an electrocardiogram (ECG). They will ask questions about how the participants are feeling and if they have any medical problems. 
Sponsor: Bayer 
Intervention: Regorafenib, (Stivarga, BAY73-4506) 
Start Date: 2021-02-03 
Last Updated: 2023-11-28 
Number of Patients: 175 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Solid Tumors

NCTID: NCT03520075 

Title: Study of ASTX029 in Subjects With Advanced Solid Tumors 
Study Summary: This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies. 
Sponsor: Astex Pharmaceuticals, Inc. 
Intervention: ASTX029 
Start Date: 2018-05-10 
Last Updated: 2023-08-04 
Number of Patients: 300 
Recruitment Status: RECRUITING 
Condition: Solid Tumor, Adult

NCTID: NCT02098343 

Title: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 
Study Summary: The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll up to a maximum of 400 patients. 
Sponsor: Aprea Therapeutics 
Intervention: APR-246 
Start Date: 2014-03 
Last Updated: 2022-10-13 
Number of Patients: 247 
Recruitment Status: COMPLETED 
Condition: Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

NCTID: NCT04197986 

Title: Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations 
Study Summary: This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or rearrangements) who have disease that is considered at high risk for recurrence with surgery alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and/or nephrectomy. Study treatment is randomized 1:1 between infigratinib or placebo with treatment up to 1 year or until invasive local, distal, or metastatic disease recurrence confirmed by independent imaging reviewer. 
Sponsor: QED Therapeutics, Inc. 
Intervention: Infigratinib 
Start Date: 2020-03-11 
Last Updated: 2023-02-02 
Number of Patients: 39 
Recruitment Status: TERMINATED 
Condition: Upper Tract Urothelial Carcinomas

NCTID: NCT04300556 

Title: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types 
Study Summary: The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer <math display="block">OC</math>, endometrial cancer <math display="block">EC</math>, non-small cell lung carcinoma <math display="block">NSCLC</math>, triple-negative breast cancer <math display="block">TNBC</math>), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A <math display="block">OC and EC participants</math> and Part B <math display="block">EC only</math>): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the use of the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days, as mitigation strategy for interstitial lung disease (ILD); and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to further evaluate the safety, tolerability and preliminary efficacy of 2 treatment regimens with farletuzumab ecteribulin (MORAb-202) in participants with advanced EC and to determine the recommended treatment regimen for further development of farletuzumab ecteribulin (MORAb-202). 
Sponsor: Eisai Inc. 
Intervention: Farletuzumab ecteribulin 
Start Date: 2020-08-06 
Last Updated: 2023-11-01 
Number of Patients: 142 
Recruitment Status: RECRUITING 
Condition: Solid Tumor

NCTID: NCT01956812 

Title: Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer 
Study Summary: The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen). 
Sponsor: Gilead Sciences 
Intervention: IMMU-107 
Start Date: 2013-12 
Last Updated: 2021-08-16 
Number of Patients: 334 
Recruitment Status: TERMINATED 
Condition: Metastatic Pancreatic Cancer

NCTID: NCT04597125 

Title: Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH 
Study Summary: Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The NAH drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer.  Participants in this study will receive either Radium-223 dichloride or a NAH therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral NAH therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain. 
Sponsor: Bayer 
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223) 
Start Date: 2020-11-09 
Last Updated: 2023-11-14 
Number of Patients: 696 
Recruitment Status: RECRUITING 
Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCTID: NCT01578655 

Title: Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer 
Study Summary: This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter, international trial. Treatment will consist of cabazitaxel/prednisone/custirsen vs. cabazitaxel/prednisone. A total of approximately 630 patients will be randomized with equal probability to the two arms. 
Sponsor: Achieve Life Sciences 
Intervention: cabazitaxel 
Start Date: 2012-08 
Last Updated: 2016-10-12 
Number of Patients: 630 
Recruitment Status: COMPLETED 
Condition: Prostate Cancer

NCTID: NCT00789633 

Title: Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer 
Study Summary: The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer. 
Sponsor: AB Science 
Intervention: Masitinib 
Start Date: 2008-11-25 
Last Updated: 2018-12-17 
Number of Patients: 353 
Recruitment Status: COMPLETED 
Condition: Pancreatic Cancer

NCTID: NCT02438007 

Title: A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC 
Study Summary: The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC). 
Sponsor: LTN PHARMACEUTICALS, INC. 
Intervention: Galeterone 
Start Date: 2015-06 
Last Updated: 2023-03-15 
Number of Patients: 953 
Recruitment Status: TERMINATED 
Condition: Prostate Cancer

NCTID: NCT04189445 

Title: Futibatinib in Patients With Specific FGFR Aberrations 
Study Summary: The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma <math display="block">iCCA</math>); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements. 
Sponsor: Taiho Oncology, Inc. 
Intervention: Futibatinib 
Start Date: 2020-08-24 
Last Updated: 2023-06-06 
Number of Patients: 115 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Advanced or Metastatic Solid Tumor

NCTID: NCT02471716 

Title: Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor 
Study Summary: This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients. 
Sponsor: Five Prime Therapeutics, Inc. 
Intervention: FPA008 
Start Date: 2015-06 
Last Updated: 2021-08-31 
Number of Patients: 66 
Recruitment Status: COMPLETED 
Condition: Pigmented Villonodular Synovitis

NCTID: NCT02983045 

Title: A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors 
Study Summary: In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3. 
Sponsor: Nektar Therapeutics 
Intervention: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab 
Start Date: 2016-12-19 
Last Updated: 2023-03-13 
Number of Patients: 557 
Recruitment Status: COMPLETED 
Condition: Melanoma

NCTID: NCT03485209 

Title: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors 
Study Summary: This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study.  * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: ** Pembrolizumab or, ** Pembrolizumab and carboplatin, or ** Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin. 
Sponsor: Seagen Inc. 
Intervention: tisotumab vedotin 
Start Date: 2018-06-25 
Last Updated: 2023-11-14 
Number of Patients: 692 
Recruitment Status: RECRUITING 
Condition: Colorectal Neoplasms

NCTID: NCT04901806 

Title: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors 
Study Summary: This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors. 
Sponsor: Pyramid Biosciences 
Intervention: PBI-200 
Start Date: 2021-07-20 
Last Updated: 2023-05-11 
Number of Patients: 74 
Recruitment Status: RECRUITING 
Condition: Solid Tumor, Adult

NCTID: NCT00312845 

Title: Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma 
Study Summary: The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below. 
Sponsor: Millennium Pharmaceuticals, Inc. 
Intervention: Bortezomib + Rituximab 
Start Date: 2006-03 
Last Updated: 2012-06-25 
Number of Patients: 676 
Recruitment Status: COMPLETED 
Condition: Non-Hodgkin’s Lymphoma

NCTID: NCT01310816 

Title: A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma 
Study Summary: IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma. 
Sponsor: Infinity Pharmaceuticals, Inc. 
Intervention: IPI-926 
Start Date: 2011-02 
Last Updated: 2013-12-05 
Number of Patients: 105 
Recruitment Status: COMPLETED 
Condition: Conventional Chondrosarcoma

NCTID: NCT00069745 

Title: Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen 
Study Summary: PURPOSE:  The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).  TARGET PATIENT POPULATION:  The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria.  WHAT IS SATRAPLATIN:  Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial.  RATIONALE:  There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy 
Sponsor: Agennix 
Intervention: Satraplatin 
Start Date: 2003-09 
Last Updated: 2012-08-07 
Number of Patients: NA 
Recruitment Status: COMPLETED 
Condition: Prostate Cancer

NCTID: NCT02730416 

Title: Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer 
Study Summary: This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer. 
Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit 
Intervention: Nintedanib or Placebo; Carboplatin, Paclitaxel 
Start Date: 2016-12-12 
Last Updated: 2023-09-21 
Number of Patients: 146 
Recruitment Status: COMPLETED 
Condition: Endometrial Cancer

NCTID: NCT02684006 

Title: A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) 
Study Summary: This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma 
Sponsor: Pfizer 
Intervention: Avelumab (MSB0010718C) 
Start Date: 2016-03-23 
Last Updated: 2023-11-09 
Number of Patients: 888 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Renal Cell Cancer

NCTID: NCT02383927 

Title: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations 
Study Summary: Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head & Neck SCC) and cohort 3 (Other SCC) are currently open 
Sponsor: Kura Oncology, Inc. 
Intervention: Tipifarnib 
Start Date: 2015-03 
Last Updated: 2021-05-14 
Number of Patients: 63 
Recruitment Status: COMPLETED 
Condition: Thyroid Cancer

NCTID: NCT03424005 

Title: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer 
Study Summary: This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer.  The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study:  Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line <math display="block">1L</math> PD-L1+ cohort).  Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line <math display="block">2L</math> CIT-naive cohort).  Cohort 3 will consist of participants with locally-advanced or metastatic HR+, HER2-negative disease with PIK3CA mutation who may or may not have had disease progression during or following previous lines of treatment for metastatic disease (HR+cohort).  Cohort 4 will consist of participants with locally-advanced or metastatic HER2+ /HER2-low disease with PIK3CA mutation who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort).  In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). In addition, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment. 
Sponsor: Hoffmann-La Roche 
Intervention: Capecitabine 
Start Date: 2018-04-02 
Last Updated: 2023-11-07 
Number of Patients: 242 
Recruitment Status: RECRUITING 
Condition: Breast Cancer

NCTID: NCT01732926 

Title: Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas 
Study Summary: The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).  An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). 
Sponsor: Gilead Sciences 
Intervention: Idelalisib 
Start Date: 2013-01-02 
Last Updated: 2018-11-16 
Number of Patients: 475 
Recruitment Status: TERMINATED 
Condition: Indolent Non-Hodgkin’s Lymphomas

NCTID: NCT03456063 

Title: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) 
Study Summary: This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody 
Start Date: 2018-04-24 
Last Updated: 2023-10-27 
Number of Patients: 453 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Non-Small-Cell Lung

NCTID: NCT03410693 

Title: Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma 
Study Summary: This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.  The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in terms of objective response rate (before: overall survivial) of urothelial carcinoma patients with FGFR positive tumors.  At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied. 
Sponsor: Bayer 
Intervention: Rogaratinib (BAY1163877) 
Start Date: 2018-05-31 
Last Updated: 2022-09-28 
Number of Patients: 175 
Recruitment Status: COMPLETED 
Condition: Carcinoma, Transitional Cell

NCTID: NCT01846416 

Title: A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] 
Study Summary: This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression.  Eligible participants will be categorized in to three groups as follows:  # Participants with no prior chemotherapy for advanced disease; # Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); # Participants who are 2L+ and previously treated for brain metastases. 
Sponsor: Genentech, Inc. 
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody 
Start Date: 2013-05-30 
Last Updated: 2019-01-08 
Number of Patients: 138 
Recruitment Status: COMPLETED 
Condition: Non-Small Cell Lung Cancer

NCTID: NCT03136627 

Title: Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC 
Study Summary: This study will evaluate the safety, tolerability, dose-limiting toxicities, MTD, and preliminary anti-tumor activity of tivozanib in combination with nivolumab in subjects with metastatic renal cell cancer. This will use a standard ‘3+3’ dose-escalation trial design. A cohort of 3 subjects will be enrolled at each dose level. If 1 of 3 subjects experiences a DLT during Cycle 1, that dose level will be expanded to 6 subjects. If 0 of 3 or ≤ 1 of 6 subjects experience a DLT during Cycle 1, escalation to the next dose will occur. If ≥ 2 of 6 subjects experience a DLT during Cycle 1, dose escalation will stop and the prior dose will be considered the MTD. This is a validated trial design for Phase 1 trials.  Following completion of the dose-escalation cohorts and determination of MTD, an expansion cohort of up to 20 subjects may be enrolled at MTD to further evaluate safety, tolerability, and preliminary anti-tumor activity of tivozanib in combination with nivolumab in the same target population. 
Sponsor: AVEO Pharmaceuticals, Inc. 
Intervention: Tivozanib 
Start Date: 2017-03-22 
Last Updated: 2021-12-06 
Number of Patients: 28 
Recruitment Status: COMPLETED 
Condition: Carcinoma, Renal Cell

NCTID: NCT05002127 

Title: A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) 
Study Summary: A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma. 
Sponsor: ALX Oncology Inc. 
Intervention: Evorpacept (ALX148) 
Start Date: 2022-01-15 
Last Updated: 2023-01-25 
Number of Patients: 450 
Recruitment Status: RECRUITING 
Condition: Gastric Cancer

NCTID: NCT03178552 

Title: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) 
Study Summary: This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays. 
Sponsor: Hoffmann-La Roche 
Intervention: Alectinib 
Start Date: 2017-09-22 
Last Updated: 2023-11-03 
Number of Patients: 1000 
Recruitment Status: RECRUITING 
Condition: Non-Small Cell Lung Cancer

NCTID: NCT01792726 

Title: A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer. 
Study Summary: TARGIT-Boost is an international randomised clinical trial designed to test the hypothesis that the tumour bed boost delivered as a single dose of targeted intraoperative radiotherapy (TARGIT-B) is superior to the conventional course of external beam radiotherapy boost (EBRT-Boost), especially in women with high risk of local recurrence. It is a pragmatic trial in which each participating centre can use the local predefined inclusion/exclusion criteria for entry into the trial. Only centres with access to the Intrabeam® (Carl Zeiss) are eligible to enter patients into the trial.  Eligible patients are those with a higher risk of local recurrence after breast conserving surgery.  After giving consent patients are randomised to either TARGIT Boost or EBRT Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at six monthly intervals for three years and then annually.  The primary endpoint is ipsilateral breast recurrence rate. Secondary endpoints are relapse-free survival, site of recurrence, overall survival (breast-cancer specific and non-breast cancer deaths) patient satisfaction and quality of life. 
Sponsor: University College, London 
Intervention: Boost to the tumour bed 
Start Date: 2013-06 
Last Updated: 2019-07-12 
Number of Patients: 1796 
Recruitment Status: UNKNOWN 
Condition: Early Breast Cancer

NCTID: NCT00083304 

Title: Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer 
Study Summary: RSR13 (efaproxiral) is a radiation sensitizer that has shown positive results in a Phase 3, randomized clinical trial of patients with brain metastases. Of 111 eligible breast cancer patients with brain metastases in that trial, 59 patients who received RSR13 prior to radiation therapy had a median survival time that was twice as long as the 52 patients who did not receive RSR13 prior to radiation therapy.  RSR13 (efaproxiral) is an experimental drug that increases the amount of oxygen released from blood into the tissues. It is well known that certain types of cancer tumors, including those in brain metastases, lack oxygen. Lack of oxygen in a tumor can reduce the effect of radiation therapy (RT). RSR13 may increase the oxygen level in brain tumors so that radiation therapy works better.  This study will enroll up to 360 women with brain metastases from breast cancer, and will evaluate if whole brain radiation therapy given with RSR13 will have a better treatment effect than whole brain radiation therapy alone. RSR13 will be infused intravenously (IV) through a central catheter placed in a central vein. Women randomized (assigned) to receive RSR13, therefore, will need to have a central catheter placed for treatment unless one is already in place. 
Sponsor: Spectrum Pharmaceuticals, Inc 
Intervention: Efaproxiral 
Start Date: 2004-02 
Last Updated: 2013-05-10 
Number of Patients: 368 
Recruitment Status: COMPLETED 
Condition: Breast Cancer

NCTID: NCT04675827 

Title: De-escalation Adjuvant Chemo in HER2+/ER-ode-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade 
Study Summary: DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II de-escalation study evaluating neoadjuvant treatment with 12 administrations of weekly IV paclitaxel 80 mg/m2 (or IV docetaxel 75 mg/m2 every 3 weeks for 4 cycles) combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab (loading dose of 1200 mg pertuzumab and 600 mg trastuzumab, followed by 600 mg pertuzumab and 600 mg trastuzumab) every 3 weeks for 4 cycles.  Surgery will be performed according to local guidelines in all subjects after neoadjuvant treatment.  After surgery, subjects who achieve a pCR (defined as pT0/Tis pN0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Subjects with residual invasive disease will receive salvage adjuvant trastuzumab emtansine (T-DM1, 3.6 mg/kg, IV every 3 weeks) for 14 cycles. In subjects whose residual invasive disease is classified per RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator’s discretion, before the 14 cycles of T-DM1.  If histopathological analysis finds that the surgical specimen from a subject with residual disease is ER-positive and/or PR-positive, adjuvant endocrine therapy may be administered concomitantly with study treatment, at the investigator’s discretion and according to local guidelines.  Adjuvant radiotherapy will be mandatory after breast-conserving surgery, whereas it will be performed according to local guidelines after mastectomy, and it will be administered concomitantly with pertuzumab and trastuzumab FDC SC in subjects who achieve a pCR, and concomitantly with T-DM1 in subjects with residual invasive disease (after anthracycline-based chemotherapy in subjects assigned to receive this treatment). 
Sponsor: Jules Bordet Institute 
Intervention: Pertuzumab and tratuzumab fixed dose combination 
Start Date: 2022-01-17 
Last Updated: 2023-09-05 
Number of Patients: 1065 
Recruitment Status: SUSPENDED 
Condition: HER2-positive Breast Cancer

NCTID: NCT03428217 

Title: CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma 
Study Summary: Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC). 
Sponsor: Calithera Biosciences, Inc 
Intervention: CB-839 
Start Date: 2018-04-24 
Last Updated: 2023-03-20 
Number of Patients: 444 
Recruitment Status: COMPLETED 
Condition: Advanced Renal Cell Carcinoma

NCTID: NCT05462717 

Title: Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors 
Study Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose. 
Sponsor: Revolution Medicines, Inc. 
Intervention: RMC-6291 
Start Date: 2022-09-19 
Last Updated: 2023-10-18 
Number of Patients: 117 
Recruitment Status: RECRUITING 
Condition: Non-Small Cell Lung Cancer (NSCLC)

NCTID: NCT03780517 

Title: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors 
Study Summary: This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738. 
Sponsor: Boston Pharmaceuticals 
Intervention: BOS172738 
Start Date: 2018-12-12 
Last Updated: 2023-10-30 
Number of Patients: 117 
Recruitment Status: COMPLETED 
Condition: Advanced Nonhaematologic Malignancies

NCTID: NCT04187404 

Title: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma 
Study Summary: This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma. 
Sponsor: Enterome 
Intervention: EO2401 
Start Date: 2020-07-23 
Last Updated: 2023-08-25 
Number of Patients: 120 
Recruitment Status: RECRUITING 
Condition: Adrenocortical Carcinoma

NCTID: NCT03941093 

Title: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer 
Study Summary: This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G

P) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer. 

Sponsor: FibroGen 
Intervention: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX 
Start Date: 2019-05-10 
Last Updated: 2022-12-27 
Number of Patients: 284 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Pancreatic Cancer Non-resectable

NCTID: NCT03102320 

Title: Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors 
Study Summary: The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.  The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.  Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule).  Treatment will continue until disease progression or until another criterion for withdrawal is met. .Efficacy will be measured by evaluating the tumor’s objective response rate. Radiological tumor assessments will be performed at defined time points until the patient’s disease progresses.  Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue will also be collected for mesothelin expression testing and biomarker analyses. 
Sponsor: Bayer 
Intervention: Cisplatin 
Start Date: 2017-05-26 
Last Updated: 2022-06-30 
Number of Patients: 173 
Recruitment Status: COMPLETED 
Condition: Neoplasms

NCTID: NCT00910091 

Title: The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer 
Study Summary: This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer. 
Sponsor: Ipsen 
Intervention: BN83495 
Start Date: 2009-08 
Last Updated: 2019-01-30 
Number of Patients: 73 
Recruitment Status: COMPLETED 
Condition: Endometrial Cancer

NCTID: NCT03377491 

Title: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) 
Study Summary: Brief Summary:  The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. 
Sponsor: NovoCure Ltd. 
Intervention: NovoTTF-200T 
Start Date: 2018-02-10 
Last Updated: 2023-04-10 
Number of Patients: 556 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Pancreas Adenocarcinoma

NCTID: NCT02292979 

Title: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. 
Study Summary: This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography ) after two cycles of chemotherapy. 
Sponsor: The Lymphoma Academic Research Organisation 
Intervention: Doxorubicin 
Start Date: 2015-03 
Last Updated: 2022-08-19 
Number of Patients: 170 
Recruitment Status: COMPLETED 
Condition: Hodgkin Lymphoma

NCTID: NCT03978039 

Title: National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group 
Study Summary: The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas <math display="block">RESOS</math> / French expert network dedicated to the pathology of sarcomas <math display="block">RREPS</math>), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas <math display="block">NETSARC</math>), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.  Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients’ outcomes.  With the financial support of the French National Cancer Institute <math display="block">Institut National du cancer \[INCa</math>). 
Sponsor: Institut Bergonié 
Intervention: Chemotherapy 
Start Date: 2010-01 
Last Updated: 2023-07-05 
Number of Patients: 20000 
Recruitment Status: RECRUITING 
Condition: Sarcoma

NCTID: NCT02360579 

Title: Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma 
Study Summary: Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen. 
Sponsor: Iovance Biotherapeutics, Inc. 
Intervention: Lifileucel 
Start Date: 2015-09 
Last Updated: 2023-07-12 
Number of Patients: 178 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Metastatic Melanoma

NCTID: NCT03631706 

Title: M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) 
Study Summary: The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules. 
Sponsor: EMD Serono Research & Development Institute, Inc. 
Intervention: M7824 
Start Date: 2018-10-01 
Last Updated: 2023-10-27 
Number of Patients: 304 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Non-small Cell Lung Cancer

NCTID: NCT03906071 

Title: Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer 
Study Summary: This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy. 
Sponsor: Mirati Therapeutics Inc. 
Intervention: Nivolumab 
Start Date: 2019-07-15 
Last Updated: 2023-10-24 
Number of Patients: 532 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCTID: NCT03556839 

Title: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix 
Study Summary: The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity.  The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin).  This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment. 
Sponsor: Grupo Español de Investigación en Cáncer de Ovario 
Intervention: Atezolizumab 
Start Date: 2018-09-25 
Last Updated: 2023-09-13 
Number of Patients: 404 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Carcinoma of the Cervix, Stage IVB

NCTID: NCT02794571 

Title: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors 
Study Summary: This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care. 
Sponsor: Genentech, Inc. 
Intervention: Atezolizumab 
Start Date: 2016-05-23 
Last Updated: 2023-09-13 
Number of Patients: 518 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Advanced/Metastatic Tumors

NCTID: NCT01802749 

Title: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer 
Study Summary: Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.  Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.  This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone. 
Sponsor: National Cancer Institute, Naples 
Intervention: Bevacizumab 
Start Date: 2013-11 
Last Updated: 2023-03-24 
Number of Patients: 406 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Recurrent Ovarian Cancer

NCTID: NCT03395197 

Title: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC 
Study Summary: This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide. 
Sponsor: Pfizer 
Intervention: Talazoparib with enzalutamide 
Start Date: 2017-12-18 
Last Updated: 2023-08-02 
Number of Patients: 1125 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: mCRPC

NCTID: NCT01556490 

Title: Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer 
Study Summary: The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere. 
Sponsor: Boston Scientific Corporation 
Intervention: TheraSphere 
Start Date: 2012-03 
Last Updated: 2023-11-08 
Number of Patients: 526 
Recruitment Status: COMPLETED 
Condition: Unresectable Hepatocellular Carcinoma

NCTID: NCT05323656 

Title: A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) 
Study Summary: The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab. 
Sponsor: Calliditas Therapeutics Suisse SA 
Intervention: Setanaxib 
Start Date: 2022-04-06 
Last Updated: 2023-08-31 
Number of Patients: 70 
Recruitment Status: RECRUITING 
Condition: Squamous Cell Carcinoma of Head and Neck

NCTID: NCT03108495 

Title: Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma 
Study Summary: Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma 
Sponsor: Iovance Biotherapeutics, Inc. 
Intervention: LN-145 
Start Date: 2017-06-22 
Last Updated: 2023-09-13 
Number of Patients: 189 
Recruitment Status: RECRUITING 
Condition: Cervical Carcinoma

NCTID: NCT02668653 

Title: Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) 
Study Summary: Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).  Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy. 
Sponsor: Daiichi Sankyo, Inc. 
Intervention: Chemotherapy 
Start Date: 2016-09-01 
Last Updated: 2023-11-18 
Number of Patients: 539 
Recruitment Status: COMPLETED 
Condition: Acute Myeloid Leukemia

NCTID: NCT03353753 

Title: Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies 
Study Summary: This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo 
Sponsor: Deciphera Pharmaceuticals LLC 
Intervention: DCC-2618 
Start Date: 2018-02-27 
Last Updated: 2022-11-21 
Number of Patients: 129 
Recruitment Status: COMPLETED 
Condition: Gastrointestinal Stromal Tumors

NCTID: NCT05059262 

Title: Study of Vimseltinib for Tenosynovial Giant Cell Tumor 
Study Summary: This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.  The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib. 
Sponsor: Deciphera Pharmaceuticals LLC 
Intervention: vimseltinib 
Start Date: 2021-10-14 
Last Updated: 2023-03-16 
Number of Patients: 120 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Tenosynovial Giant Cell Tumor

NCTID: NCT02367794 

Title: A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] 
Study Summary: This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody 
Start Date: 2015-06-11 
Last Updated: 2022-03-21 
Number of Patients: 1021 
Recruitment Status: COMPLETED 
Condition: Squamous Non-Small Cell Lung Cancer

NCTID: NCT03872947 

Title: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors 
Study Summary: The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Topotecan, and Pegylated liposomal doxorubicin (PLD) for selected advanced solid tumors. 
Sponsor: Toray Industries, Inc 
Intervention: TRK-950 
Start Date: 2019-04-26 
Last Updated: 2023-11-18 
Number of Patients: 169 
Recruitment Status: RECRUITING 
Condition: Solid Tumor

NCTID: NCT03465722 

Title: (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST 
Study Summary: This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs. 
Sponsor: Blueprint Medicines Corporation 
Intervention: avapritinib 
Start Date: 2018-03-26 
Last Updated: 2022-10-06 
Number of Patients: 476 
Recruitment Status: COMPLETED 
Condition: GIST

NCTID: NCT00430365 

Title: Maintenance Therapy Using Lenalidomide in Myeloma 
Study Summary: Maintenance treatment of myeloma. 
Sponsor: University Hospital, Toulouse 
Intervention: lenalidomide 
Start Date: 2006-06 
Last Updated: 2019-04-26 
Number of Patients: 614 
Recruitment Status: COMPLETED 
Condition: Myeloma

NCTID: NCT01763164 

Title: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma 
Study Summary: Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival 
Sponsor: Pfizer 
Intervention: MEK162 
Start Date: 2013-07-12 
Last Updated: 2021-03-22 
Number of Patients: 402 
Recruitment Status: COMPLETED 
Condition: Metastatic or Unresectable Cutaneous Melanoma

NCTID: NCT02083653 

Title: Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer 
Study Summary: This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs). 
Sponsor: Symphogen A/S 
Intervention: Sym004 (12 mg/kg) 
Start Date: 2014-03-06 
Last Updated: 2019-04-16 
Number of Patients: 254 
Recruitment Status: COMPLETED 
Condition: Metastatic Colorectal Cancer

NCTID: NCT01485861 

Title: Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy 
Study Summary: This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of apitolisib administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone. 
Sponsor: Genentech, Inc. 
Intervention: Abiraterone 
Start Date: 2012-01-11 
Last Updated: 2023-09-14 
Number of Patients: 298 
Recruitment Status: COMPLETED 
Condition: Prostate Cancer

NCTID: NCT05459129 

Title: A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) 
Study Summary: This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab 
Start Date: 2023-04-13 
Last Updated: 2023-11-07 
Number of Patients: 90 
Recruitment Status: RECRUITING 
Condition: Squamous Cell Carcinoma of the Head and Neck

NCTID: NCT01739764 

Title: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol 
Study Summary: This open-label, multicenter, non-randomized study provided continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol’s criteria for disease progression, or were treated beyond progression and were still deriving clinical benefit (as assessed by investigator), and may have therefore potentially benefited from continued treatment with vemurafenib. Participants received treatment with oral vemurafenib at 960 milligrams (mg) twice daily (BID), 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol. Treatment continued until progression of disease or as long as the participant was deriving clinical benefit, as judged by the investigator (case-by-case decision with approval of the Medical Monitor), death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the Sponsor to terminate the study, whichever occurred first. 
Sponsor: Hoffmann-La Roche 
Intervention: Vemurafenib 
Start Date: 2013-02-19 
Last Updated: 2021-01-07 
Number of Patients: 215 
Recruitment Status: COMPLETED 
Condition: Neoplasms

NCTID: NCT04921553 

Title: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) 
Study Summary: This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion.  This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications. 
Sponsor: Centre Leon Berard 
Intervention: Data collection and quality of life questionnaire 
Start Date: 2021-06-22 
Last Updated: 2021-08-02 
Number of Patients: 500 
Recruitment Status: RECRUITING 
Condition: Cancer

NCTID: NCT01909453 

Title: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma 
Study Summary: This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized.  Part 1:  Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms:  # LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm) # LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or # vemurafenib 960 mg BID (denoted as vemurafenib arm)  Part 2:  Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms:  # LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or # LGX818 300 mg QD monotherapy (denoted as LGX818 arm) 
Sponsor: Pfizer 
Intervention: LGX818 
Start Date: 2013-12-13 
Last Updated: 2023-09-07 
Number of Patients: 921 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Melanoma

NCTID: NCT05330429 

Title: Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) 
Study Summary: The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).  The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC). 
Sponsor: Gilead Sciences 
Intervention: Magrolimab 
Start Date: 2022-07-08 
Last Updated: 2023-11-02 
Number of Patients: 135 
Recruitment Status: RECRUITING 
Condition: Metastatic Colorectal Cancer

NCTID: NCT01261429 

Title: Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) 
Study Summary: The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT) who cannot be treated by surgery.  The primary objective of the study will be to determine the efficacy of 12 weeks (3 months) of nilotinib treatment as measured by the non progression rate (Complete response + Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours - RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery.  this study is an international, multicentre, non-randomized, open-label phase II clinical trial with a Bayesian design.  A maximum sample size of 50 patients will be included in the study 
Sponsor: Centre Leon Berard 
Intervention: Tasigna 
Start Date: 2010-12 
Last Updated: 2013-04-16 
Number of Patients: 50 
Recruitment Status: COMPLETED 
Condition: Pigmented Villonodular Synovitis

NCTID: NCT01743469 

Title: A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers 
Study Summary: This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who had progressed after standard therapies. 
Sponsor: Ipsen 
Intervention: Tasquinimod 
Start Date: 2012-12 
Last Updated: 2019-01-08 
Number of Patients: 201 
Recruitment Status: COMPLETED 
Condition: Advanced or Metastatic Hepatocellular Cancer

NCTID: NCT03850535 

Title: A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission 
Study Summary: This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine and daunorubicin in induction, in combination with cytarabine in consolidation, and as a single agent in maintenance for treating participants with acute myeloid leukemia (AML). 
Sponsor: Hoffmann-La Roche 
Intervention: Idasanutlin 
Start Date: 2019-03-25 
Last Updated: 2022-06-21 
Number of Patients: 24 
Recruitment Status: TERMINATED 
Condition: Acute Myeloid Leukemia

NCTID: NCT02428842 

Title: Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4) 
Study Summary: Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points. 
Sponsor: Institut Curie 
Intervention: Tumor biopsies 
Start Date: 2013-10-24 
Last Updated: 2023-01-20 
Number of Patients: 419 
Recruitment Status: COMPLETED 
Condition: Cervical Cancer

NCTID: NCT01991210 

Title: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) 
Study Summary: This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram (mg/kg) intravenously (IV) every 3 weeks or PLD 40 milligrams per meter-squared (mg/m^2) IV every 4 weeks. 
Sponsor: Genentech, Inc. 
Intervention: DNIB0600A 
Start Date: 2014-02-06 
Last Updated: 2017-08-21 
Number of Patients: 95 
Recruitment Status: TERMINATED 
Condition: Ovarian Cancer

NCTID: NCT03970746 

Title: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDClung01 Cancer Vaccine in NSCLC 
Study Summary: PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer. 
Sponsor: PDCline Pharma SAS 
Intervention: PDC*lung01 
Start Date: 2019-09-10 
Last Updated: 2023-10-24 
Number of Patients: 73 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Non Small Cell Lung Cancer

NCTID: NCT04246489 

Title: Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer 
Study Summary: The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy. 
Sponsor: EMD Serono Research & Development Institute, Inc. 
Intervention: Bintrafusp alfa 
Start Date: 2020-03-30 
Last Updated: 2023-10-23 
Number of Patients: 146 
Recruitment Status: COMPLETED 
Condition: Uterine Cervical Neoplasms

NCTID: NCT00924989 

Title: A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma 
Study Summary: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens 
Sponsor: Astellas Pharma Inc 
Intervention: OSI-906 
Start Date: 2009-12-01 
Last Updated: 2018-09-05 
Number of Patients: 139 
Recruitment Status: COMPLETED 
Condition: Adrenocortical Carcinoma

NCTID: NCT02348489 

Title: SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction 
Study Summary: To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy. 
Sponsor: Astex Pharmaceuticals, Inc. 
Intervention: SGI-110 (guadecitabine) 
Start Date: 2015-03-19 
Last Updated: 2021-01-14 
Number of Patients: 815 
Recruitment Status: COMPLETED 
Condition: Leukemia, Myeloid, Acute

NCTID: NCT04892173 

Title: NBTXR3 With or Without Cetuximab in LA-HNSCC 
Study Summary: This is a global, open-label, randomized, 2-arm, Investigator’s choice Phase 3 (Pivotal Stage) study to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC. 
Sponsor: Nanobiotix 
Intervention: NBTXR3 
Start Date: 2022-01-05 
Last Updated: 2023-01-03 
Number of Patients: 500 
Recruitment Status: RECRUITING 
Condition: Locally Advanced Head and Neck Squamous Cell Carcinoma

NCTID: NCT03945773 

Title: Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors 
Study Summary: The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy. 
Sponsor: Ipsen 
Intervention: Cabozantinib 
Start Date: 2020-01-08 
Last Updated: 2023-10-26 
Number of Patients: 127 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Locally Advanced or Metastatic Renal Cell Carcinoma

NCTID: NCT05389462 

Title: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors 
Study Summary: The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine. 
Sponsor: ADC Therapeutics S.A. 
Intervention: ADCT-601 
Start Date: 2022-07-13 
Last Updated: 2023-10-05 
Number of Patients: 196 
Recruitment Status: RECRUITING 
Condition: Advanced Solid Tumors

NCTID: NCT01122472 

Title: Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP 
Study Summary: This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to explore the effect of maintenance therapy with lenalidomide versus placebo on progression-free survival (PFS) in patients treated with R-CHOP responding to induction therapy  For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs 73.6%), is considered clinically relevant. 
Sponsor: The Lymphoma Academic Research Organisation 
Intervention: Lenalidomide 
Start Date: 2009-04 
Last Updated: 2021-07-26 
Number of Patients: 650 
Recruitment Status: COMPLETED 
Condition: Lymphoma

NCTID: NCT03134638 

Title: A Study of SY-1365 in Adult Patients With Advanced Solid Tumors 
Study Summary: This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2.  Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology. 
Sponsor: Syros Pharmaceuticals 
Intervention: SY-1365 (Part 1) 
Start Date: 2017-05-12 
Last Updated: 2021-03-09 
Number of Patients: 107 
Recruitment Status: TERMINATED 
Condition: Advanced Solid Tumors

NCTID: NCT04887831 

Title: Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab 
Study Summary: This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer. 
Sponsor: G1 Therapeutics, Inc. 
Intervention: Trilaciclib 
Start Date: 2021-06-04 
Last Updated: 2023-09-13 
Number of Patients: 92 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Urothelial Carcinoma

NCTID: NCT01373710 

Title: Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis 
Study Summary: The purpose of this study is:  Phase I: To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route to reach a intra CSF target concentration (30 µg/mL) near the conventional therapeutic concentration and depending on the dose-limiting toxicity (DLT)  Phase II: Determination of antitumor activity trastuzumab when administrated by IT or intra-ventricular in terms of neurological progression-free survival at 2 months 
Sponsor: Institut Curie 
Intervention: Trastuzumab 
Start Date: 2011-05-19 
Last Updated: 2019-07-10 
Number of Patients: 34 
Recruitment Status: COMPLETED 
Condition: Metastatic Breast Cancer

NCTID: NCT03767348 

Title: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab 
Study Summary: RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy. 
Sponsor: Replimune Inc. 
Intervention: RP1 
Start Date: 2017-09-20 
Last Updated: 2023-08-02 
Number of Patients: 340 
Recruitment Status: RECRUITING 
Condition: Cancer

NCTID: NCT05329766 

Title: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies 
Study Summary: This is a Phase 2, open-label, parallel 3-cohort, multicenter study to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil). 
Sponsor: Arcus Biosciences, Inc. 
Intervention: Domvanalimab 
Start Date: 2022-06-10 
Last Updated: 2023-08-31 
Number of Patients: 200 
Recruitment Status: RECRUITING 
Condition: Gastrointestinal Tract Malignancies

NCTID: NCT02420821 

Title: A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) 
Study Summary: This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody 
Start Date: 2015-05-20 
Last Updated: 2023-01-30 
Number of Patients: 915 
Recruitment Status: COMPLETED 
Condition: Renal Cell Carcinoma

NCTID: NCT00873119 

Title: Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary 
Study Summary: The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary. 
Sponsor: Onxeo 
Intervention: belinostat, carboplatin, paclitaxel 
Start Date: 2009-02 
Last Updated: 2015-07-28 
Number of Patients: 89 
Recruitment Status: COMPLETED 
Condition: Carcinoma of Unknown Primary

NCTID: NCT03436485 

Title: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer 
Study Summary: The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer. 
Sponsor: Orion Corporation, Orion Pharma 
Intervention: ODM-208 
Start Date: 2018-03-19 
Last Updated: 2023-03-23 
Number of Patients: 192 
Recruitment Status: RECRUITING 
Condition: Prostate Cancer Metastatic

NCTID: NCT01997333 

Title: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer 
Study Summary: The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. The study will also further characterize the safety of CDX-011 treatment in this patient population. 
Sponsor: Celldex Therapeutics 
Intervention: CDX-011 
Start Date: 2013-11 
Last Updated: 2019-03-08 
Number of Patients: 327 
Recruitment Status: COMPLETED 
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

NCTID: NCT05099172 

Title: First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) 
Study Summary: Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.  Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer.  Several EGFR and/or HER2 mutations exist in the cancer cells. Two mutations observed in NSCLC are called EGFR- or HER2exon20ins and EGFR C797X. The study treatment, BAY2927088, works by blocking the mutated EGFR protein and also its ex20ins version which are present in NSCLC. It is also believed to work against HER2 and HER2ex20ins mutations. Researchers think this may help stop the further spread of NSCLC cancer.  This is the first time that researchers will study BAY2927088 in humans. In this study, the researchers want to learn more about using BAY2927088 in participants who have NSCLC with EGFR and/or HER2 mutations including EGFRex20ins and/or HER2ex20ins mutations.  The main aims of this study are to find for BAY2927088  * how safe BAY2927088 is * how it affects the body (also referred to as tolerability) * how BAY2927088 moves into, through and out of the body * the maximum amount of BAY2927088 that the participants can take without too many side effects.  The researchers will also study the action of BAY2927088 against the cancer. The study will have three parts: Dose Escalation, Backfill, and Dose Expansion. Each participant of the first, so called dose escalation part, will be assigned to one of specific sequential dose groups for BAY2927088. The amount of BAY2927088 that is given increases stepwise from one group to the next.  The second may be initiated at any dose that has already been tested during the first part and found to be safe and to have either reached a predicted efficacious exposure range or to have induced an objective response. The first part and second part will run concurrently.  The participants of the third, so called dose expansion part, will receive the most appropriate dose of BAY2927088 found in the first and second parts. The third part may be initiated in parallel with the first and second part based on emerging data.  During the study, the participants will take the study treatment in 3 week periods called “cycles”. They will in general take BAY2927088 once daily until their cancer gets worse, until they have medical problems, until they leave the study or until the study is terminated. Participants will have around 5 visits in each cycle.  During the study, the study team will:  * take blood and urine samples * take regular CT or MRI scans to check if the participants’ cancer has gotten better or worse * check the participants’ overall health and heart health * ask the participants questions about how they are feeling and what adverse events they are having.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. 
Sponsor: Bayer 
Intervention: BAY2927088_formulation A 
Start Date: 2021-10-25 
Last Updated: 2023-11-28 
Number of Patients: 340 
Recruitment Status: RECRUITING 
Condition: Advanced Non-small Cell Lung Cancer

NCTID: NCT03063762 

Title: Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) 
Study Summary: This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab 
Start Date: 2017-03-20 
Last Updated: 2023-02-17 
Number of Patients: 69 
Recruitment Status: COMPLETED 
Condition: Renal Cell Carcinoma

NCTID: NCT02678572 

Title: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma 
Study Summary: This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment. 
Sponsor: Delcath Systems Inc. 
Intervention: Melphalan/HDS 
Start Date: 2016-02-01 
Last Updated: 2023-04-03 
Number of Patients: 102 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Melanoma, Ocular

NCTID: NCT02541604 

Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors 
Study Summary: This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab 
Start Date: 2015-11-30 
Last Updated: 2020-02-25 
Number of Patients: 87 
Recruitment Status: TERMINATED 
Condition: Solid Tumor

NCTID: NCT01772004 

Title: Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) 
Study Summary: This is a Phase 1, open-label, dose-escalation trial of avelumab <math display="block">antibody targeting programmed death ligand 1 (anti PD-L1)</math> with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts.  Active cohorts: Escalation revised dosing regimen cohort.  Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase . 
Sponsor: EMD Serono Research & Development Institute, Inc. 
Intervention: Avelumab 
Start Date: 2013-01-31 
Last Updated: 2021-12-20 
Number of Patients: 1756 
Recruitment Status: COMPLETED 
Condition: Solid Tumors

NCTID: NCT02629692 

Title: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies 
Study Summary: Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML 
Sponsor: Sun Pharma Advanced Research Company Limited 
Intervention: Vodobatinib (K0706) capsules 
Start Date: 2017-04-25 
Last Updated: 2023-10-27 
Number of Patients: 122 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Healthy (For Part A)

NCTID: NCT03525392 

Title: Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. 
Study Summary: This study was being conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1). This study was a first administration of a radioactive drug called 177Lu-3BP-227 to patients under controlled conditions of a clinical study. The purpose of this study is to evaluate how safe this investigational drug is as well to verify how well it is tolerated by patients after several intravenous administrations. In addition, the effect of the study drug on tumoral lesions and how it distributes throughout the body and at which rate it is removed from the body was evaluated. Since 177Lu-3BP-227 is a radio-labelled drug, it will also be measured how the emitted radiation is distributed throughout the body (dosimetry).  The study consisted of a phase I dose escalation part. The study originally planned to include a phase II study however due to early termination (not due to safety concerns) the study did not progress to phase II and was stopped during phase I. For the phase I dose escalation part, it was anticipated that approximately 30 subjects will be included, in up to six escalation steps. No expansion cohorts were implemented. 
Sponsor: Ipsen 
Intervention: 177Lu-3BP-227 (also called 177Lu-IPN01087) 
Start Date: 2018-05-03 
Last Updated: 2021-06-07 
Number of Patients: 14 
Recruitment Status: TERMINATED 
Condition: Pancreatic Ductal Adenocarcinoma

NCTID: NCT02052778 

Title: A Study of TAS-120 in Patients With Advanced Solid Tumors 
Study Summary: This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of futibatinib in patients with advanced solid tumors with and without genomic FGF/FGFR abnormalities. The study will be conducted in 3 parts:  # Dose escalation portion to determine the MTD and/ or RP2D of futibatinib. # Phase 1 expansion portion to further evaluate the safety and efficacy of futibatinib in patients with tumors harboring FGF/FGFR aberrations, including patients with cholangiocarcinoma (CCA), primary CNS tumors, urothelial carcinoma, breast cancer, gastric cancer. # Phase 2 study portion to confirm ORR of futibatinib in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions). 
Sponsor: Taiho Oncology, Inc. 
Intervention: Futibatinib 
Start Date: 2014-07 
Last Updated: 2022-01-10 
Number of Patients: 386 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Cholangiocarcinoma

NCTID: NCT03009058 

Title: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer 
Study Summary: During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient’s specific tumour type.  The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens. 
Sponsor: Immodulon Therapeutics Ltd 
Intervention: IMM-101 
Start Date: 2017-05-24 
Last Updated: 2018-08-09 
Number of Patients: 2 
Recruitment Status: TERMINATED 
Condition: Metastatic Cancer

NCTID: NCT04628494 

Title: A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL 
Study Summary: The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of epcoritamab has already been studied in previous studies in humans, the main purpose of this study is to evaluate efficacy. To evaluate this, half of the participants who are eligible will receive epcoritamab and the other half will receive a pre-specified investigator’s choice of chemotherapy. Epcoritamab will be studied in R/R DLBCL participants who did not respond to a previous autologous stem cell transplant (ASCT) or do not meet the criteria for ASCT 
Sponsor: Genmab 
Intervention: Epcoritamab 
Start Date: 2021-01-13 
Last Updated: 2023-08-07 
Number of Patients: 552 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Diffuse Large B-cell Lymphoma

NCTID: NCT03793478 

Title: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood 
Study Summary: Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment. 
Sponsor: Daiichi Sankyo, Inc. 
Intervention: Quizartinib 
Start Date: 2018-08-15 
Last Updated: 2023-10-13 
Number of Patients: 65 
Recruitment Status: RECRUITING 
Condition: Acute Myeloid Leukemia

NCTID: NCT01303094 

Title: Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma 
Study Summary: This randomization discontinuation trial will allow for concomitant evaluation of the following:  * Side effects and benefits of immediate continuation of Trabectedin after the sixth cycle * Side effects and benefits of a drug holiday 
Sponsor: Centre Oscar Lambret 
Intervention: Trabectedin 
Start Date: 2011-02 
Last Updated: 2019-05-31 
Number of Patients: 53 
Recruitment Status: COMPLETED 
Condition: Soft Tissue Sarcoma

NCTID: NCT03306394 

Title: A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). 
Study Summary: The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).  Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor’s prescription or can be accessed from another source or Sponsor decision. 
Sponsor: Institut de Recherches Internationales Servier 
Intervention: Trifluridine/Tipiracil hydrochloride (S95005) 
Start Date: 2016-10-18 
Last Updated: 2021-11-17 
Number of Patients: 907 
Recruitment Status: COMPLETED 
Condition: Metastatic Colorectal Cancer

NCTID: NCT04774718 

Title: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Study Summary: This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available. 
Sponsor: Hoffmann-La Roche 
Intervention: Alectinib 
Start Date: 2021-09-14 
Last Updated: 2023-11-07 
Number of Patients: 42 
Recruitment Status: RECRUITING 
Condition: ALK Fusion-positive Solid or CNS Tumors

NCTID: NCT03786094 

Title: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer 
Study Summary: This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer. 
Sponsor: Spexis AG 
Intervention: Eribulin 
Start Date: 2019-05-30 
Last Updated: 2023-11-01 
Number of Patients: 432 
Recruitment Status: TERMINATED 
Condition: Metastatic Breast Cancer

NCTID: NCT01569295 

Title: Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela) 
Study Summary: The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL) 
Sponsor: Gilead Sciences 
Intervention: Idelalisib 
Start Date: 2012-06-15 
Last Updated: 2020-03-10 
Number of Patients: 416 
Recruitment Status: COMPLETED 
Condition: Chronic Lymphocytic Leukemia

NCTID: NCT05183984 

Title: Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovarian Cancer 
Study Summary: Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab. 
Sponsor: ARCAGY/ GINECO GROUP 
Intervention: Chemotherapy 
Start Date: 2022-02-01 
Last Updated: 2022-12-06 
Number of Patients: 390 
Recruitment Status: RECRUITING 
Condition: Ovarian Cancer

NCTID: NCT05587296 

Title: A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer 
Study Summary: Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy.  VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer.  It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.  The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.  The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it.  To answer this, the doctors will ask the participants to record information about their hot flashes before treatment start and at certain time points during the treatment in an electronic diary. The researchers will then assess possible average changes in number and severity of hot flashes after 4 and 12 weeks of treatment.  To see how safe elinzanetant is compared to placebo. The study will collect information about the number of participants who have medical problems after taking treatment.  The study participants will be randomly (by chance) assigned to 2 treatment groups, A and B. The participants from treatment group A will take elinzanetant. The participants from treatment group B will start with placebo and then switch to elinzanetant.  All participants will continue taking the anti-cancer therapy they have been using when entering the study.  Dependent on the treatment group, the participants will either take elinzanetant or placebo as capsules by mouth once a day. After 12 weeks, the participants who have initially received placebo will switch to take elinzanetant for the remaining 40 weeks.  Each participant will be in the study for approximately 62 weeks. The treatment duration in the study will be 52 weeks. There will be up to 12 visits to the study site and 6 phone calls in between. Participants who completed the 52 weeks treatment phase, will be offered to continue treatment for another 2 years. Visit frequency: every 24 weeks until week 152.  During the study, the participants will:  * record information about their hot flashes * answer questions about their quality of life and other symptoms.  The doctors and their study team will:  * check the participants health and vital signs * take blood and urine samples * examine heart health using electrocardiogram (ECG) * examine pelvic organs like womb or ovaries using a trans vaginal ultrasound scan to see images of these organs * make images of the breast using x-ray (mammogram), a type of radiation that passes through the body to make images of the inside and/or by using ultrasound (if applicable) * check the health of the participant’s cervix (neck of the womb) by taking a small sample of cells (smear test) for an analysis called cervical cytology (if applicable) * take an endometrial biopsy, a small piece of tissue from the lining of the womb (called the endometrium) for analysis. * ask the participants questions about what medicines they are taking and if they are having adverse events.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.  About 4 weeks after the participants take their last treatment, the study doctors and their team will check the participants’ health. 
Sponsor: Bayer 
Intervention: Elinzanetant (BAY3427080) 
Start Date: 2022-10-14 
Last Updated: 2023-11-13 
Number of Patients: 405 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCTID: NCT01526928 

Title: Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients 
Study Summary: Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral rociletinib; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral rociletinib; to assess the safety and efficacy of rociletinib in previously treated NSCLC patients known to have the T790M EGFR mutation. 
Sponsor: Clovis Oncology, Inc. 
Intervention: Rociletinib 
Start Date: 2012-03-27 
Last Updated: 2020-08-04 
Number of Patients: 612 
Recruitment Status: TERMINATED 
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCTID: NCT03669718 

Title: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC 
Study Summary: This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b. 
Sponsor: ISA Pharmaceuticals 
Intervention: ISA101b 
Start Date: 2018-11-30 
Last Updated: 2023-04-12 
Number of Patients: 194 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Squamous Cell Carcinoma of the Oropharynx

NCTID: NCT02975934 

Title: A Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency 
Study Summary: The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician’s choice of abiraterone acetate, enzalutamide, or docetaxel. 
Sponsor: pharmaand GmbH 
Intervention: Rucaparib 
Start Date: 2017-06-13 
Last Updated: 2023-11-07 
Number of Patients: 405 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Metastatic Castration Resistant Prostate Cancer

NCTID: NCT03673501 

Title: A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib 
Study Summary: This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off). 
Sponsor: Deciphera Pharmaceuticals LLC 
Intervention: DCC-2618 
Start Date: 2019-02-11 
Last Updated: 2021-01-06 
Number of Patients: 426 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Gastrointestinal Stromal Tumors

NCTID: NCT04050436 

Title: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer 
Study Summary: To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review. 
Sponsor: Replimune Inc. 
Intervention: Cemiplimab 
Start Date: 2019-10-08 
Last Updated: 2023-02-03 
Number of Patients: 231 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Cutaneous Squamous Cell Carcinoma

NCTID: NCT05275478 

Title: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors 
Study Summary: This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants. 
Sponsor: Tango Therapeutics, Inc. 
Intervention: TNG908 
Start Date: 2022-03-23 
Last Updated: 2023-08-01 
Number of Patients: 192 
Recruitment Status: RECRUITING 
Condition: Locally Advanced Solid Tumor

NCTID: NCT00718523 

Title: Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer 
Study Summary: This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma. 
Sponsor: Translational Research in Oncology 
Intervention: AMG 479 
Start Date: 2009-01 
Last Updated: 2016-01-12 
Number of Patients: 170 
Recruitment Status: TERMINATED 
Condition: Ovarian Neoplasms

NCTID: NCT01957436 

Title: A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer 
Study Summary: This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer. 
Sponsor: UNICANCER 
Intervention: abiraterone acetate 
Start Date: 2013-11-13 
Last Updated: 2023-11-08 
Number of Patients: 1173 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Metastatic Prostate Cancer

NCTID: NCT04797780 

Title: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome 
Study Summary: This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms. 
Sponsor: Syros Pharmaceuticals 
Intervention: Tamibarotene 
Start Date: 2021-02-08 
Last Updated: 2023-11-15 
Number of Patients: 550 
Recruitment Status: RECRUITING 
Condition: Myelodysplastic Syndromes

NCTID: NCT01796002 

Title: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma 
Study Summary: Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC). 
Sponsor: The Lymphoma Academic Research Organisation 
Intervention: Romidepsin + CHOP 
Start Date: 2013-01 
Last Updated: 2023-01-10 
Number of Patients: 421 
Recruitment Status: COMPLETED 
Condition: Peripheral T-cell Lymphoma

NCTID: NCT02511678 

Title: Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases 
Study Summary: This study will evaluate the efficacy of cryoablation for palliation of painful metastases in participants with metastatic lesions involving bone who have failed, are not candidates for, or are not experiencing adequate pain relief from current pain therapies (for example, radiation, analgesics). 
Sponsor: Boston Scientific Corporation 
Intervention: Cryoablation 
Start Date: 2016-02-15 
Last Updated: 2021-07-19 
Number of Patients: 73 
Recruitment Status: COMPLETED 
Condition: Pain

NCTID: NCT05566795 

Title: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) 
Study Summary: This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy. 
Sponsor: Day One Biopharmaceuticals, Inc. 
Intervention: DAY101 
Start Date: 2023-02-27 
Last Updated: 2023-11-22 
Number of Patients: 400 
Recruitment Status: RECRUITING 
Condition: Low-grade Glioma

NCTID: NCT00642395 

Title: Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) 
Study Summary: Intensification with autologous stem cell

hasTrialTitle::Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy hasTrialTitle::A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC hasTrialTitle::Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors hasTrialTitle::A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL hasTrialTitle::D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma hasTrialTitle::A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer hasTrialTitle::Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer hasTrialTitle::Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer hasTrialTitle::A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) hasTrialTitle::A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer hasTrialTitle::A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer hasTrialTitle::A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors hasTrialTitle::Study of ASTX029 in Subjects With Advanced Solid Tumors hasTrialTitle::p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 hasTrialTitle::Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations hasTrialTitle::A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types hasTrialTitle::Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer hasTrialTitle::Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH hasTrialTitle::Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer hasTrialTitle::Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer hasTrialTitle::A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC hasTrialTitle::Futibatinib in Patients With Specific FGFR Aberrations hasTrialTitle::Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor hasTrialTitle::A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors hasTrialTitle::Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors hasTrialTitle::Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors hasTrialTitle::Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma hasTrialTitle::A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma hasTrialTitle::Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen hasTrialTitle::Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer hasTrialTitle::A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) hasTrialTitle::Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations hasTrialTitle::A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer hasTrialTitle::Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas hasTrialTitle::A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) hasTrialTitle::Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma hasTrialTitle::Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC hasTrialTitle::A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) hasTrialTitle::A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) hasTrialTitle::A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer hasTrialTitle::Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer hasTrialTitle::De-escalation Adjuvant Chemo in HER2+/ER-ode-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade hasTrialTitle::CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma hasTrialTitle::Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors hasTrialTitle::Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors hasTrialTitle::A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma hasTrialTitle::Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer hasTrialTitle::Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors hasTrialTitle::The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer hasTrialTitle::Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) hasTrialTitle::Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma hasTrialTitle::National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group hasTrialTitle::Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma hasTrialTitle::M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) hasTrialTitle::Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer hasTrialTitle::Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix hasTrialTitle::Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors hasTrialTitle::Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer hasTrialTitle::Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC hasTrialTitle::Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer hasTrialTitle::A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) hasTrialTitle::Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma hasTrialTitle::Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) hasTrialTitle::Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies hasTrialTitle::Study of Vimseltinib for Tenosynovial Giant Cell Tumor hasTrialTitle::A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131 hasTrialTitle::A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors hasTrialTitle::(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST hasTrialTitle::Maintenance Therapy Using Lenalidomide in Myeloma hasTrialTitle::Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma hasTrialTitle::Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer hasTrialTitle::Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy hasTrialTitle::A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) hasTrialTitle::An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) hasTrialTitle::Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma hasTrialTitle::Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) hasTrialTitle::Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) hasTrialTitle::A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers hasTrialTitle::A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission hasTrialTitle::Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4) hasTrialTitle::A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) hasTrialTitle::Safety, Immunogenicity and Preliminary Clinical Activity Study of PDClung01 Cancer Vaccine in NSCLC hasTrialTitle::Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer hasTrialTitle::A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma hasTrialTitle::SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction hasTrialTitle::NBTXR3 With or Without Cetuximab in LA-HNSCC hasTrialTitle::Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors hasTrialTitle::A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors hasTrialTitle::Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP hasTrialTitle::A Study of SY-1365 in Adult Patients With Advanced Solid Tumors hasTrialTitle::Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab hasTrialTitle::Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis hasTrialTitle::Study of RP1 Monotherapy and RP1 in Combination With Nivolumab hasTrialTitle::A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies hasTrialTitle::A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) hasTrialTitle::Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary hasTrialTitle::Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer hasTrialTitle::Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer hasTrialTitle::First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) hasTrialTitle::Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) hasTrialTitle::Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma hasTrialTitle::Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) hasTrialTitle::Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies hasTrialTitle::Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1 hasTrialTitle::A Study of TAS-120 in Patients With Advanced Solid Tumors hasTrialTitle::Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer hasTrialTitle::A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL hasTrialTitle::Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood hasTrialTitle::Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma hasTrialTitle::A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic) hasTrialTitle::A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors hasTrialTitle::Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer hasTrialTitle::Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela) hasTrialTitle::Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovarian Cancer hasTrialTitle::A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer hasTrialTitle::Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients hasTrialTitle::A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC hasTrialTitle::A Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency hasTrialTitle::A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib hasTrialTitle::Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer hasTrialTitle::Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors hasTrialTitle::Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer hasTrialTitle::A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer hasTrialTitle::Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome hasTrialTitle::Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma hasTrialTitle::Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases hasTrialTitle::DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) hasTrialTitle::Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) hasCancerType::C00-D48: All neoplasms hasCancerType::C00-C97: All cancer types hasCancerType::C00-C14: Mouth/throat cancers hasCancerType::C15-C26: Digestive system cancers hasCancerType::C30-C39: Lung/chest cancers hasCancerType::C40-C41: Bone cancers hasCancerType::C43-C44: Skin cancers/melanoma hasCancerType::C45-C49: Soft tissue cancer hasCancerType::C50: Breast cancer hasCancerType::C51-C58: Female genitalia cancers hasCancerType::C60-C63: Male genitalia cancer hasCancerType::C64-C68: Urinary system cancers hasCancerType::C69-C72: Eye and brain cancer hasCancerType::C73-C75: Thyroid and other gland cancers hasCancerType::C76-C80: Cancers of unknown or unspecified areas hasCancerType::C81-C96: Cancers of the blood and immune system hasCancerType::C97-C97: Cancers in multiple locations from the start hasCancerType::D00-D09: Early-stage cancers not yet spread hasCancerType::D10-D36: Benign tumour hasCancerType::D37-D48: Growths of uncertain nature hasCancerType::unknown isTrial

Retrieved from "https://wiki.beaconcancer.org/index.php?title=Trials_(Léon_Bérard_Center)&oldid=35530"
Powered by MediaWiki
Powered by Semantic MediaWiki